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CHAPTER 1  
 
 
INTRODUCTION 
 
1.1 General introduction 
Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology. It is a 
rare disorder with an incidence in adults of approximately 20 new cases per million 
per year (1). Genetic and environmental factors such as toxins and infections have 
been identified to be associated with SSc (2, 3). Its pathogenesis is characterized 
by vasculopathy, autoimmunity, and cytokine dysbalance, altogether leading to 
fibrosis of the skin and inner organs (Figure 1) (4). These features vary between 
patients, but it seems clear that SSc pathogenesis is characterized by a complex 
interplay between these factors. There is a high heterogeneity in clinical 
presentation of SSc e.g. limited versus diffuse SSc, early vs. chronic disease, or 
early vs. late onset SSc, that have to be taken into consideration when studying 
this disease (5). Along the important progress in inflammation research that has 
been made during the last decade in general, inflammation has also attracted 
increasing attention in SSc (6). Both the innate and adaptive immune system 
participates in SSc pathogenesis. The importance of the immune system in SSc 
has also been demonstrated in cases where SSc patients underwent autologous or 
allogeneic stem cell transplantation. Conditioning e.g. with cyclophosphamide 
followed by reinfusion of stem cells markedly improved the disease course (7). Cell 
infiltrates in SSc affected dermis mainly consist of T- and B lymphocytes, 
macrophages, and mast cells. These cells release profibrotic mediators which then 
stimulate fibroblasts to secrete extracellular matrix (ECM) proteins (8-10). The 
inflammatory cells are responsible for a profibrotic cytokine milieu, typically 
characterized by Th2 cytokines (11). 
Humoral autoimmunity in the form of autoantibodies has been postulated to 
contribute to SSc progression, e.g. by autoantibodies against endothelial cells or 
fibroblasts (12). Although B-cells clearly occur in the inflamed SSc tissue and 
certainly are of importance, the pathogenic relevance of autoantibodies in SSc 
remains controversial (13).  
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This work contributes to the understanding of SSc by further analyses of the 
cellular pathogenesis and cytokines involved in SSc. Both experimental and clinical 
studies have been performed in this thesis, analysing different inflammatory cell 
types and cytokines and patient subgroups, respectively. 
 
Figure 1. Sequential steps in the pathogenesis of SSc (14)  
 
 
 
1.2 Animal models of SSc 
Important lessons have been learned on the role of inflammation in SSc, by animal 
models (15-19). SSc animal models are classified into genetic models (e.g. TSK, 
Fra-2, Caveolin 1 -/- mice) or SSc-inducible models (e.g. bleomycin induced SSc, 
or sclerodermatous graft versus host disease) (20). The most widely used animal 
model of SSc is the bleomycin-induced SSc model. Bleomycin is used in humans 
because it has anti-tumor effects in different types of cancer. In higher doses, 
bleomycin can induce lung injury and pulmonary fibrosis (21) and bleomycin 
stimulates isolated fibroblasts to produce collagen (22). Case reports described 
skin fibrosis that occurred after treatment with bleomycin. Usually, mice receive 
bleomycin by daily subcutaneous injections over 4 weeks. When instilled in the 
lung, bleomycin has been used to study murine pulmonary fibrosis (23). Bleomcyin 
treated mice develop skin fibrosis which usually persists for several weeks after the 
treatment and lung fibrosis characterized by cellular infiltrates and lung 
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parenchymal damage. Also, anti-Scl-70 auto-antibodies develop in the course of 
bleomycin treatment, reflecting a state of autoimmunity or loss of tolerance to self 
antigens, respectively (24). The severity of skin fibrosis depends on the strain; 
B10.A strain e.g. shows a high susceptibility. Skin thickening in bleomycin treated 
mice is associated with inflammatory changes. Macrophages, eosinophils, mast 
cells, but also T- and B-lymphocytes are attracted and promote fibrosis presumably 
by activation of fibroblasts, or the differentiation into myofibroblasts. This is 
associated with a pro-fibrotic cytokine milieu, notably with increased levels of 
transforming growth factor (TGF) beta, IL-4, IL-6, IL-13 and platelet derived growth 
factor (PDGF) (25). Which of the above mentioned cells are mainly responsible 
e.g. for TGF-beta expression is elusive. In fact, inflammatory cell infiltration, 
cytokines and specific inflammation receptor pathway activation have been 
identified as ‘sine qua non’ for fibrosis (18, 26-30). The transfer of T-cells from 
bleomycin treated into healthy mice led to the development of SSc. Limitations of 
the bleomycin model are the lack of systemic disease features, the spontaneous 
improvement and possibly the overestimation of anti-inflammatory compounds 
(20). 
As an important limitation in SSc animal models in general, not all pathogenic 
features that are observed in humans are found in the animals. E.g. vasculopathy, 
as important pathogenic feature is usually not observed in bleomycin induced skin 
fibrosis, scleroderma like GvHD or Tsk-1 mice. However, newer SSc animal 
models such as Fra-2 or UCD-200/2006 mice do present this feature and might be 
more useful for some studies.  
Chronic GvHD occurs in a substantial part of patients who received allogeneic 
stem cell transplantation. Clinically, GvHD resembles SSc by skin thickening and 
lung fibrosis; GvHD due to microchimerism has been discussed as a possible 
cause for SSc (31). In the animal model, alloreactive T cells seem the most 
important cell type involved in the pathogenesis of chronic GVHD. As also 
observed in the bleomycin mouse model, naive CD4 T cells are sufficient and 
necessary to provoke SSc-like GvHD. In contrast, the transfer of CD8 T cells does 
not cause the disease phenotype.  
In contrast to other models, mast cell counts decrease in mice with SSc-GVHD 
mice (32). Mast cell degranulation and infiltration is postulated to enhance 
 10 
fibroblasts to release ECM proteins fibroblasts (32). It is however unclear what 
exactly stimulates mast cells and triggers the degranulation. 
 
1.3 Clinical presentation of SSc  
The disease course of SSc is chronic and highly heterogeneous with a spectrum 
ranging from a limited cutaneous affection to a diffuse systemic form of the 
disease. Raynaud’s syndrome typically precedes other clinical manifestations. Skin 
tightening, contractures, calcification and ulcers frequently lead to functional 
impairment and changes in appearance. 
 
 
Figure 2. Hand of a patient with limited SSc showing Raynaud  
phenomenon, digital ulcers, calcinosis cutis and sclerodactyly.  
With permission of the patient. 
 
 At a later stage, fibrosis of internal organs can lead to respiratory or cardiac 
insufficiency or renal failure. Limited SSc is typically associated with clinical 
features of vasculopathy in the form of digital ulcers and pulmonary hypertension. 
In contrast, diffuse SSc typically manifests as skin thickening and lung fibrosis. 
Limited SSc is commonly associated with the CREST syndrome consisting of 
calcinosis cutis, Raynaud phenomenon, esophageal dysmobility, sclerodactyli and 
teleangiectasia. Skin involvement is the most common feature in SSc. Skin 
thickening and hardening are the typical findings in advanced disease. At an earlier 
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stage, edematous swelling, erythema, and pruritus may occur. Skin thickening is 
quantified by the Rodnan skin score, estimating the severity of skin thickness, 
pliability and fixation to underlying structures in 17 distinct areas of the body from 0 
(normal) to 3 (most severe) (33).  
A positive anti-centromere (ACA) autoantibody status is associated with limited 
disease whereas anti-topoisomerase (anti-Scl70) antibodies commonly are 
associated with diffuse SSc. Renal crisis occurs more frequently in patients with 
rapid progression of diffuse SSc. Cardiac involvement is also more prevalent in 
diffuse SSc patients. Patients with a rapid progression have a lower 10-year 
cumulative survival rate (34). 
 
 
1.4 Aging and immunosenescence in SSc 
Age is an important factor in the disease presentation of autoimmune diseases (5, 
35). Immunosenescence is defined as changes in the immune system that develop 
with increasing age. This phenomenon is likely to interfere with the course of SSc. 
Aging can affect both the innate and adaptive immune system, both of which are 
involved in SSc pathogenesis. Several studies postulate an impaired function of 
the macrophage / monocyte cell line in older individuals (36). Impaired 
phagocytosis, reduced toll like receptor expression and a change in cytokine 
expression occur along aging processes (37). Whereas IL-6 and TNF-alpha 
expression of monocytes decreased in cells from aged mice, IL-10 levels 
increased upon stimulation (38). CD16+ monocytes have attracted increasing 
interest in autoimmune diseases during the last years. Interestingly, CD16+ 
expression on monocytes and polymorphonuclear neutrophils is reduced in the 
elderly (39).    
T-lymphocyte immunity is even more affected by ageing, resulting in decreased 
numbers of naive T cells, impaired antigen response and proliferation, increased 
memory cells, and alterations in apoptosis (36). The cytokine expression pattern 
shifts towards a Th2 response (40). During aging, the thymus becomes atrophic 
and the function of the thymus reduces subsequently. This results in a decreased 
T-cell receptor diversity and a reduced central tolerance. Naive T-cell counts 
decrease with aging, and the proportion of memory T cells increases. Upon 
antigen stimulation, naïve CD4+ T cells from aged mice produce less IL-2 
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compared with younger animals (41). This indicates that lymphocytes in older 
individuals might also react less severe on stimulation by auto-antigens.  
The reduced capability of the central tolerance is compensated by peripheral 
tolerance, notably via T-regulatory cells. However, the function of T-regulatory cells 
in aged individuals seems to be impaired as well, although existing reports are 
controversial (42). B-cells are also decreased in the elderly, notably naïve B-cells. 
This is probably due to less IL-7. Specific antibodies are also decreased in the 
elderly and less antibodies against self-antigens have been described (43). 
Increased levels of antinuclear autoantibodies (ANA) in the elderly that are 
frequently encountered typically affect individuals with chronic disease rather than 
successfully aging individuals (44). Generally, elderly populations show less organ-
specific autoantibodies compared to non organ-specific autoantibodies such as 
ANA. It is not clear which mechanisms are responsible for autoantibody production 
in the elderly, but failed suppressor cell function and the loss of central tolerance is 
likely to be involved. There are other theories why autoimmunity may increase with 
aging. Activation of B-cellls presentation of ‘neoantigens’ is one of them (45). 
Alteration of apoptosis in T-cells or the influence of long term cytomegaly infection 
on the immune system have also been discussed (46). A ‘risk’ phenotype of the 
elderly to develop autoimmune diseases consists of low B cell levels, increased 
CD8+CD28- cell rates, poor T cell proliferation response, decreased CD4/CD8 ratio 
<1 and CMV seropositivity (47, 48).  
SSc patients with a juvenile onset have less skin involvement and lower mortality 
rates, but they do suffer more frequently from overlap syndromes, typically 
involving skeletal muscles (49). Conversely, patients with onset of Raynaud’s 
phenomenon above the mean age suffer more frequently from digital ulcers, lung 
fibrosis, PH and diastolic heart failure (50). The mean age at onset of first non-
Raynaud’s phenomenon in the EULAR Scleroderma Trials and Research 
(EUSTAR) database was reported 44.8 years for diffuse SSc and 47.9 years for 
limited SSc (50). Generally, white patients have an older age at diagnosis 
compared to black patients (43.8 years) (51). Among white patients, the peak 
incidence was between 65 and 74 years in women and >75 years in white men 
(51). The incidence of SSc >75 years is around 20 cases per million per year 
which is 2-4% of all SSc cases (51). 
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Late age at onset of SSc has been reported to be associated with a more 
aggressive disease course (52). The risk of death increases by 5% for each 1-year 
increase in age at diagnosis (51). The number of patients >75 years at diagnosis in 
previous studies however is low and naturally occurring co-morbidity in the elderly 
certainly influences survival analysis. Only small SSc cohorts or case series have 
focused on late onset SSc. Whereas some cases presented with a more severe 
disease course compared to patients <60 years, a more benign course, especially 
concerning skin involvement, has been reported by others (53-55). Despite a more 
severe lung involvement and a delayed diagnosis in the late onset group, the 
disease remained stable in patients >75 years (55). These results and the above 
mentioned known mechanisms of immunosenescence let to the investigation of 
late onset SSc. The hypothesis was that due to immunosenescence, the course of 
SSc in patients with a late onset of the disease is less aggressive compared to the 
control group.   
 
1.5 Genetic predisposition  
The discovery of genetic polymorphisms and mutations in a disease of unknown 
cause such as SSc is important to identify impaired signaling pathways, cytokines 
or receptors. Following their identification, functional analyses are usually 
performed to confirm a pathogenic mechanism and develop possible drug 
candidates. The completion of the human genome sequence and the advent of 
efficient and affordable genome-wide association studies (GWAS) have greatly 
enhanced the discovery and investigation of many new gene mutation candidates 
(in particular, single nucleotide polymorphisms, [SNPs]) in SSc and autoimmune 
diseases in general (see http://genome.gov/gwastudies). A recent study suggests 
that there is a familial predominance in SSc, notably affecting the prevalence of RP 
and interstitial lung disease. Genetic predisposition to vasculopathy is the most 
frequent risk among first-degree relatives in SSc pedigrees (56). 
Polymorphisms of the connective-tissue growth factor (CTGF) gene (57), the 
protein tyrosine phosphatase non-receptor type 22 gene, interleukin-10 receptor 
gene, STAT-4 and interferon-regulating factor are associated with a genetic 
susceptibility to SSc (58).  
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Several polymorphisms have been reported within TNF-signalling or TNF-
receptors: the genotype TNFA-1031T/T is associated both with diffuse SSc and 
limited SSc (59). Furthermore, AG/AA genotypes in position -238 and the AG 
genotype in position +489 of the TNF-alpha gene are significantly increased in 
patients with SSc. The relatively rare GG genotype in exon 6 of the TNF-R2 gene 
is also increased in SSc, although not significant (60).  
The described polymorphism within the TNF or interferon pathway however, lack 
mechanistical evidence. TNF-alpha and TNF-R2 gene polymorphisms were 
important factors for me to carry out mechanistic research on TNF in SSc.  
 
 
1.6 Cytokine environment  
Cytokines are essential mediators of tissue homeostasis through their regulation of 
cell-growth, -interaction, -migration, and -differentiation, but also stimulation of the 
production and degradation of extracellular matrix (ECM). In SSc patients, 
imbalances of the cytokine environment have been described in tissue and serum 
(61). Both pro- and anti-inflammatory cytokines are increased (Table 1) (62); the 
exact significance of this counter-play is still elusive. In general, a shift in Th1 
polarization towards Th2 cells is observed (63).  
Numerous cytokines such as IL-4 and -13 are upregulated in SSc serum. They 
stimulate the expression of collagen in fibroblasts, and the differentiation of 
monocytes into fibrocytes or myofibroblasts. TGF-beta, one of the most potent 
profibrotic cytokines in our body, plays a key role in SSc pathogenesis as it 
stimulates collagen expression by fibroblasts via the SMAD transcription factor 
pathway and also mediates the differentiation of monocytes into myofibroblasts. In 
SSc skin, TGF-beta is mainly expressed perivascularly within mononuclear 
infiltrates (64). Once secreted, TGF-beta remains in the ECM in a latent form, until 
it is activated by integrins and serine proteases (65). In contrast to the findings in 
tissue, the TGF-beta levels in the serum of SSc patients are decreased (66).  
Platelet derived growth factor (PDGF) is another important profibrotic protein. In 
SSc, elevated levels of PDGF have been reported in skin, serum and fluid obtained 
by bronchoalveolar lavage (63). It is a potent chemoattractant for monocytes, 
macrophages and fibroblasts. Like TGF-beta, PDGF stimulates proliferation of 
fibroblasts, especially in the presence of high concentrations. The exact cellular 
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source both of TGF-beta and PDGF is not clear. Both immune cells and fibroblasts 
have been shown to express the growth factors, but it remains unclear on a protein 
level which cells are mainly responsible for their excretion in SSc.  
IL-6 is a pro-inflammatory cytokine that is elevated in SSc sera and correlates with 
disease severity. Fibroblasts of SSc patients produce more IL-6 compared with 
fibroblasts from healthy individuals. Monocyte chemoattractant protein-1 (MCP-1; 
also known as CCL2) is a chemotactic protein that recruits monocytes, memory T 
cells, and dendritic cells to the site of inflammation (6). Elevated MCP-1 levels 
have been described in the early stage of SSc and correlate with organ-based 
complications (67). Tumor necrosis factor-alpha (TNF-alpha) has been shown to 
be an important cytokine in inflammation although its exact role in SSc remains 
controversial. TNF receptors are overexpressed in SSc skin and both TNF-alpha 
and soluble TNF receptor levels are higher in sera of SSc patients (16).The latter 
correlates with inflammation and disease progression. Upregulation of TNF-alpha-
converting enzyme (TACE), which sheds the receptors and soluble TNF-alpha 
from the cell surface, has been described in peripheral monocytes of SSc patients 
(68). Functional data on TNF-alpha in SSc demonstrate that it inhibits collagen 
expression in fibroblasts (69), presumably by a downregulation of TGF-beta 
receptor 2 (70). 
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Cytokine Findings in SSc Translational status 
Profibrotic:   
TGF-beta Elevated in tissue, reduced in serum, 
increased TGF-beta receptor 
expression, increased activation of 
latent TGF-beta by integrins 
Clinical- trial with mAb. 
Negative outcome   
IL-4, IL-13 Increased collagen production, 
myofibroblasts differentiation 
- 
PDGF Receptor stimulation by autoantibodies - 
Inflammatory:   
IL-6 Elevated in serum - 
MCP-1 Elevated in tissue, correlation with 
disease activity  
 
Unclear:   
TNF-alpha Increased in serum and tissue, 
upregulation of TACE in monocytes, 
inhibition of collagen production in 
fibroblasts 
Infliximab effective in 
animal models and case 
series, negative clinical 
trials  
Type 1 IFN Elevated in tissue, monocyte activation  Mab under investigation 
in SLE, not tested in SSc 
 
Table 1. Cytokines and chemokines involved in systemic sclerosis and current status of treatment 
with inhibitory antibodies. TGF-beta: transforming growth factor-beta. TGF-beta receptor; Mab: 
monoclonal antibody; IL: interleukin; PDGF: platelet-derived growth factor; MCP-1: monocyte 
chemoattractant protein-1; TNF-alpha: tumor necrosis factor-alpha; TACE: TNF-alpha-converting 
enzyme; IFN: interferon; SLE: Systemic lupus erythematosus 
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Type 1 interferons (IFNs) include IFN-alpha and -beta and have recently been 
shown to be involved in SSc pathogenesis. Case series described the occurrence 
of SSc during or after treatment with IFN-alpha or -beta in patients with hepatitis C, 
multiple sclerosis, and myelodysplastic syndrome, and remission or stabilization of 
SSc symptoms were described after cessation of treatment (71). In a previous 
clinical trial using IFN-alpha as a possible treatment for SSc, deleterious effects 
have been described (72). Increased levels of IFN are found perivascularly in the 
skin and serum of SSc patients (73). Compared with monocytes from healthy 
controls, monocytes from patients with SSc have been found to express 
significantly increased levels of IFN-regulated genes such as Siglec-1 (CD169) 
(74). Incubation of peripheral blood mononuclear cells (PBMCs) from healthy 
controls with sera from SSc patients (containing anti-topoisomerase I 
autoantibodies) led to overexpression of type 1 IFN (75) . 
 
 
1.7 Vascular dysfunction  
The clinical observation of Raynaud’s phenomenon as a first clinical sign and the 
perivascular mononuclear infiltrate observed in the early phase of SSc suggest an 
endothelial involvement as one of the initial pathogenic steps in SSc (76). 
Capillaroscopy has evolved as an important diagnostic tool in SSc, especially in 
early disease (77). One pathogenic concept is cross-reactivity of antiviral (e.g. 
cytomegalovirus, CMV) antibodies with endothelial structures. A molecular mimicry 
in which antibodies recognize both the human CMV late protein UL94 and the 
integrin–novel antigen-2 (NAG-2) complex can lead to apoptosis of endothelial 
cells (78). Indeed, the incubation of healthy endothelial precursor cells (EPC) with 
serum of SSc patients leads to apoptosis, confirming that SSc sera contain 
apoptosis-inducing factors (79). Another possible pathogenic mechanism of 
vasculopathy is the insufficient supply of functional EPC. In the bone marrow of 
SSc patients, reduced numbers of functionally impaired EPC have been described 
(80). Another study showed abnormal endothelial cell differentiation from bone 
marrow-derived mesenchymal stem cells (MSC) (81). 
Endothelin-1 (ET-1), a peptide secreted from endothelial cells is elevated in SSc. 
Its production leads to constriction of the underlying smooth muscle cells. ET-1 
stimulates fibroblasts to produce and contract ECM. Blockade of ET-1 leads to a 
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reduction of type 1 collagen and alpha-smooth muscle actin (alpha-SMA) by these 
cells (82).  
 
 
1.8 Autoimmunity  
Both humoral and cellular features of autoimmunity are found in SSc. A T-cell 
proliferative response to type 1 collagen has been reported patients with SSc (83). 
Autoantibodies that are classically associated with SSc are anti-centromere 
antibodies (ACA) and the anti-topoisomerase I (anti-Scl-70). Although most of the 
infiltrating cells in affected skin in SSc are T-lympocytes, a B-cell gene expression 
signature has also been demonstrated (84). Increased serum levels of BAFF (B-
cell activating factor), a potent B cell survival factor, have been detected and 
positively correlate with the severity of skin fibrosis.  
The influence of B-cell in SSc has been nicely studied in the TSK mouse model 
which present a similar systemic autoimmunity than SSc patients (20) TSK mice 
show hyper-gamma-globulinemia and autoantibodies against topoisomerase I, 
fibrillin 1, RNA polymerase I, collagen type I, and Fc-receptors (85). CD19 
expression is increased in SSc patients and CD19 signalling pathway is constantly 
activated in TSK mice (86). B-cell depletion in TSK mice reduces skin thickening 
(87). 
Over the last few years, a substantial range of new autoantibodies with a possible 
pathogenic role in SSc have been discovered (Table 2). Anti-endothelial cell 
antibodies have been shown to induce apoptosis in human dermal microvascular 
endothelial cells (88). Anti-fibroblast antibodies directed against the protein fibrillin-
1 have been detected in a significant proportion of SSc patients. They activate 
fibroblasts in vitro via the TGF-beta pathway, resulting in increased ECM 
production (89). Anti-matrix metalloproteinase (anti-MMP) antibodies have been 
shown to be directed against MMP-1 and MMP-3, which prevent ECM degradation 
and thus may promote fibrosis (90). Anti-platelet-derived growth factor (anti-PDGF) 
antibodies have been reported to recognize and activate the human PDGF 
receptor and to stimulate reactive oxygen species (ROS) and collagen production 
(12). More recently, anti-angiotensin receptor and anti-endothelin receptor 
autoantibodies have been demonstrated to be associated with more severe 
disease manifestations and to predict SSc-related mortality. (91) 
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Table 2. Autoantibodies in systemic sclerosis. ACA: anti-centromere antibodies; ECM: extracellular 
matrix; MMP: matrix metalloproteinase; PDGF: platelet-derived growth factor; NAG-2: novel 
antigen-2; TGF-beta: transforming growth factor-beta. 
  
 
 
1.9 Fibrosis  
Fibrosis is a biological process involving an inflammatory response and 
subsequent overproduction of ECM proteins. Cytokines, especially TGF-beta, have 
an important role in the development of fibrosis. The transcription factor T-box 
expressed in T cells (T-bet) has recently been identified as important regulator of 
skin sclerosis (92). Knockout of T-bet, the main regulator of the Th1 immune 
response, led to skin fibrosis via an IL-13-dependent pathway. This is associated 
with a predominant Th2 response, including the over-expression of TGF-beta. 
Interestingly, T-bet-deficient CD4 T cells were sufficient to transfer bleomycine 
induced pulmonary disease to unaffected SCID recipients (93). T-bet regulated 
transcription is of importance both for cellular members of the innate and adaptive 
immune system. FoxP3 positive cells upregulate their T-bet and T-bet positive T-
regulatory cells accumulate at sites of TH1 cell–mediated inflammation (94). Thus, 
homeostasis of T-regulatory cells is dependent on T-bet, at least in a Th1 setting. 
Autoantibody Target Pathogenicity 
ACA  Centromeres Not known 
Scl-70 Topoisomerase Not known 
Anti-endothelial  NAG-2 Apoptosis, ECM expression 
Anti-fibroblast Fibrillin-1 
NAG-2 
ECM expression via TGF-
beta pathway 
fibroblast activation/ECM 
expression 
Anti-MMP MMP-1 and -3 Inhibition of ECM 
degradation 
Anti-PDGF PDGF receptor Collagen expression, 
production of reactive oxygen 
species 
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Whether or not reduced T-bet expression has a pathogenic significance in SSc, 
remains elusive. 
A classic dogma in fibrosis is the observation that fibroblasts or myofibroblasts 
overproduce collagen. Another concept is the endothelial–mesenchymal transition 
(EMT) in which endothelial cells are transformed into matrix-producing cells such 
as myofibroblasts. A third, yet unproven theory is the recruitment of circulating 
fibrocytes (95). Fibrocytes constitute a bone marrow-derived cell type of the 
monocytic lineage that have a physiological function in wound healing and might 
be of importance in fibrosis.  
Taking into account that the ECM undergoes a constant turnover, the impaired 
breakdown of the matrix may also result in fibrosis. More specifically, the inhibition 
of metalloproteinases by tissue inhibitors of metalloproteinases (TIMPs) results in a 
reduced ECM breakdown. In SSc, levels of both TIMP-1 and -2 are raised in serum 
and correlate with disease severity (96). SSc fibroblasts express higher levels of 
TIMP-1 mRNA compared with healthy controls (97).  
 
 
 
1.10 Inflammatory cell infiltration and the loss of tolerance in SSc 
Several factors such as cytokines or chemokines which trigger the influx of 
immune cells are important in the initiation of inflammation. On the other side, the 
resolution of inflammation and restoration of tolerance has been increasingly 
recognized in inflammation research (6). Or, in other words, the problem with 
inflammation often is not how it starts, but how it fails to subside (98). The switch 
from a pro- into an anti-inflammatory cell phenotype and cytokines, apoptosis, and 
transport of cell debris, respectively seem to be essential events for the resolution 
of inflammation (98). 
The ‘orchestration’ of inflammation is pivotal in understanding and probably also 
treating auto-inflammatory disorders. In SSc, both the innate and adaptive arms of 
the immune system are involved. Skin and lung biopsies from SSc patients 
showed increased numbers of lymphocytes, monocytes and mast cells, typically 
located around affected vessels (8, 10, 76, 99, 100). This is in line with SSc animal 
models such as bleomycine, silica or asbestos induced SSc, where inflammatory 
cell infiltration, cytokines and specific inflammation receptor pathway activation 
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have been identified as ‘sine qua non’ for fibrosis (18, 26-30) (see animal model 
section). The first cells entering SSc induced tissue damage are monocytes (8). 
Monocytes which differentiate into macrophages or dendritic cells once they have 
left the circulation are an important source of inflammatory cytokines such as TNF-
alpha and chemokines thus attracting other cell types. In this phase, macrophages 
belong to the so called M1 type (101). However, monocytes can also differentiate 
into fibrocytes, pericytes or myofibroblasts and therefore have the capacity to 
produce ECM (95). In wound healing, a specific macrophage phenotype which is 
involved in tissue repair has been postulated (102). A M2 phenotype of 
macrophages orchestrate the ECM in wound by secretion of tissue proteases and 
thus actively remodelling the tissue (101). Older studies confirm already that mice 
with non functioning macrophages have a delayed wound healing (103). 
 
 
1.11 Mast cells 
Mast cells are granule-containing secretory cells resident in the connective tissue, 
notably in the skin, respiratory system and gastrointestinal tract. Activation such as 
in hypersensitivity or anaphylaxis leads to the release of various tissue mediators, 
including vasoactive amines, proteinases and also TGF-beta (104, 105). Their 
proximity to fibroblasts makes mast cell products available to fibroblasts and 
stimulates them to produce collagen (105, 106).  
Mast cells promote wound healing by secretion of growth mediators and interaction 
with other cell types. They release histamine, prostaglandins and leukotriens, 
causing early vasodilatation and venule permeability, but they also release 
inflammatory mediators such as TNF-alpha, IL-6 and IL-1. Mast cells accumulate 
around injured tissue were they release mast cell tryptase. Tryptase not only 
stimulates collagen expression by fibroblasts, but also triggers wound contraction 
by stimulating alpha-SMA expression. Animal models showed that wound 
contraction is insufficient in the absence of mast cells (107). Mast cells interact with 
fibroblasts via gap-junctions (108).  
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Figure 3. RMC-1 Mast cells passing Calcein Acetomethoxy dye into fibroblasts.  
Taken from (109). 
 
Several mechanisms can provoke mast cell degranulation. In IgE mediated 
reactions, antigen binds with mast cell surface IgE. This is notably encountered in 
anaphylaxis or helmintic infections were metabolic products of the helmints bind 
IgE. But also tissue injury, mechanical stress, heat, irradiation, toxins, venoms or 
complement are known to induce mast cell degranulation (110).  
Mast cells also express several receptors by which they can be activated and 
degranulated. Of those, Fc receptors such as activating IgG receptor FcγRIIa 
(CD32a) in the resting state, and, in the presence of interferon-γ, the high affinity 
activating FcγRI (CD64) (111). Other receptors expressed on mast cells are C3a 
and C5a receptors, IL-3R, IL-4R, IL-5R, IL-9R, IL-10R, GM-CSFR, IFN-γR and 
CCR3, CCR5, CXCR2, CXCR4, nerve growth factor receptor, and toll-like 
receptors (TLRs). 
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Figure 4. key inflammatory mediators produced by mast cells. IL, interleukin; TNF, tumour necrosis 
factor; TGF, transforming growth factor; PDGF, platelet-derived growth factor. Taken from (112). 
 
In SSc, the number of mast cells is increased both in involved and uninvolved skin 
and the number of de-granulated mast cells is increased in the involved but not in 
the uninvolved skin (113).  
The results obtained in this thesis support the hypothesis of inflammation as a key 
factor in the aetiology of SSc: The roles of mast cells and monocytes as members 
of the innate and lymphocytes as member of the adaptive immune system are 
further clarified. It is illustrated that mast cells in SSc are activated, appear in 
higher numbers, and importantly, are the major source of transforming growth 
factor (TGF)-beta, a pivotal growth factor in SSc (10). The factor triggering mast 
cell degranulation in SSc, however remain elusive.  
 
1.12 TNF and TNF-receptors in SSc 
Tumor necrosis factor (TNF) alpha is a highly pleiotropic cytokine with paramount 
influence on the initiation and orchestration of inflammation in general (114). It also 
has been postulated that TNF-alpha is a key mediator of the transition from 
inflammation to fibrosis (17). One of the core projects of this thesis was to 
investigate the role of TNF alpha receptors (TNF-R) in SSc. This was based on the 
fact that TNF-R are profoundly involved in autoimmunity and even profibrotic 
effects of TNF-R have been postulated (115). A distinct upregulation of TNF-R has 
been demonstrated in SSc skin samples, notably TNF-R2 expression on 
monocuclear cell infiltrates in SSc is high (16). The role of TNF in fibrosis is 
controversial (116). It is commonly accepted that TNF alpha per se inhibits 
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collagen expression of fibroblasts, at least in healthy individuals (69, 117). TNF-
knock out animals fail to develop asbestos, silica or bleomycine induced lung 
fibrosis (29) and accordingly, TNF-blockade has been shown to prevent fibrosis in 
bleomycine or silica animal models (118). In this context, TNF-R2 seems to be of 
special importance in the development of fibrosis as TNF-R2 knock out mice are 
protected from fibrosis (119). 
Until recently, TNF alpha signalling was mainly supposed to function via TNF-R1, 
which possesses a death domain and activates a pro-inflammatory cascade 
including NF-kappaB (120, 121) (Figure 5). In contrast to TNF-R1, TNF-R2 has no 
death domain and signals via the recruitment of a so called TRAF-interacting 
domain. 
 
Soluble TNF
Membrane bound TNF
TNF-R1 TNF-R2
Cell membrane
FADD TRADD
MADD
Caspases
Apoptosis
JNK
Transcription
C-Jun
C-JFos
TRAF TRAF
CIAP
RIP
NIKMEKKs
ERKs p38
NF-kB
Gene expression
•Inflammation
•Cell survival
•Resolution of inflammation
Cell proliferation
NF-kB
Death domain TRAF-interacting domain
 
 
Figure 5. Downstream TNF-R signalling. TRADD: TNF Receptor Associated Death Domain, RIP: 
Receptor Interacting Protein, RIP: TRAF =TNF Receptor Associated Factor. 
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The main role of TNF-R2 was believed to be restricted to a bystander role in form 
of ligand passing to TNF-R1 (120). However, within the last decade, important 
structural and functional properties have revealed an increasing role of TNF-R in 
inflammation and notably the resolution of inflammation. In chronic inflammation 
models, TNF- and TNF-R deficient mice develop more severe inflammation (122). 
One hypothesis for the observation of possible TNF regulated immunosuppressive 
feedback effects was that TNF promotes the expansion of T-regulatory cells. 
Indeed it was demonstrated that active or resting T-regulatory cells express more 
TNF-R2 than other T-effector cells (123) Interestingly, and possibly corresponding 
to clinical observations in sepsis where acute inflammation is followed by a 
immunosuppressive state (124). TNF abrogates inhibitory T-regulatory function on 
T-effector cells proliferation initially. This is followed, however, by a restoration of 
T-regulatory function, after longer exposure to TNF. Similar to IL-2, TNF 
upregulates FoxP3 expression on T-regulatory cells (123). This effect was not 
observed on TNF-R2 knock out animals, supporting an immunosuppressive role of 
this receptor in inflammation. The duration of TNF exposure is also important for T-
cell signalling: chronic TNF-alpha exposure impairs TCR-signalling via TNF-R2 but 
not TNF-R1 (125). Shedding of TNF-R2 from the cell surface by TNF alpha 
converting enzyme (TACE), releases TNF-R2 (126). Subsequently, TNF-R2 can 
inactivate TNF (as ‘natural’ TNF-blocking compound) and therefore represents an 
anti-inflammatory mechanism, which has been successfully translated into clinical 
medicine by the development of etanercept (127) Also a physiological intrinsic anti-
inflammatory and even profibrotic property, has been attributed to TNF-R2 by 
triggering e.g. IL-10 expression (119, 123, 128-132). Profibrotic effects upon 
prolonged TNF exposure might be supported by the fact that in animal models of 
sustained airway inflammation, TNF drives remodeling of blood vessels and 
lymphatics (26). 
It remains elusive why TNF blockade is an efficient treatment in humans in some 
autoimmune diseases and has little effect in others. In RA, spondylarthritis or 
inflammatory bowel diseases, anti-TNF compounds have been successfully 
translated into clinical application. On the other side, anti-TNF treatment does not 
lead to remission in all patients, or in others, only for a short period of time (133). 
Furthermore, autoimmune epiphenomena have been described under TNF-
blockade, such as episodes of lupus, multiple sclerosis or neuropathy (134). In 
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SSc, a clinical trial with infliximab failed to demonstrate a significantly positive 
effect on skin thickening albeit the collagen expression in the dermis was 
significantly lower compared to the control (135). These findings reflect the 
necessity for a deeper understanding of TNF biology in SSc before the right SSc 
patients can be selected for treatment.   
In this thesis, multicolour flow cytometry of the skin was for the first time applied to 
investigate TNF-R expression on various inflammatory dermal cell subsets. 
Furthermore, the availability of TNF-R selective TNF mutants for this study allowed 
a precise functional analysis of both receptors. Indeed, lymphocytes overexpress 
IL-6, an important proinflammatory and profibrotic cytokine, mainly upon TNF-R1 
activation. TGF-beta, a key profibrotic cytokine, is expressed in first line upon TNF-
R2 activation. It could also be demonstrated that, in vitro, TNF-R2 as activation 
marker, is overexpressed on the cell surface after CD3/28 stimulation. In healthy 
CD3/28 activated lymphocytes, stimulation of TNF-R2 led to an increased 
expression of the anti-inflammatory cytokine IL-10 when compared to activated 
lymphocytes from SSc patients. This might point to a dysregulation of the 
resolution of inflammation process.   
 
 
1.13 Therapeutic strategies   
 
1.13.1 Background therapy 
Most SSc patients will use symptomatic medication, such as proton-pump 
inhibitors for reflux, calcium channel antagonists for vasodilatation, and an 
angiotensin-converting enzyme (ACE) inhibitor or angiotensin (AT) -II receptor 
antagonist for the prevention of renal crisis. ACE or AT-II inhibitors inhibit TGF-
beta production and have shown antifibrotic effects in liver fibrosis; the significance 
for that in SSc however has not been investigated so far. Other background 
medication such as aspirin and statins are prescribed depending on co-morbidity 
and cardiovascular risk factors. In vitro, statins can also reduce TGF-beta 
production. Further treatment depends on the stage of the disease and the organs 
involved. In the following, we discuss already available therapeutics or upcoming 
strategies of the different pathogenic features of SSc.   
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1.13.2 Vasoactive medication  
Digital ulcers and Raynaud’s phenomenon lead to a reduction in quality of life and 
pulmonary hypertension and renal crisis are life-threatening manifestations of SSc. 
Much effort has therefore been put into development of an efficient treatment of 
SSc vasculopathy. ET-1 has been demonstrated to participate directly in the 
vascular damage (136). The ET-1 inhibitor bosentan is currently approved for use 
in pulmonary hypertension (grade 2 to 4) and the prevention of digital ulcers in 
SSc. A positive effect of bosentan was illustrated by a long-term improvement and 
disease stability in patients with grade 3 pulmonary hypertension (137). This was 
confirmed in another study in which bosentan improved New York Heart 
Association class and hemodynamics (138). Other ET-1 inhibitors that are 
successfully used in pulmonary hypertension are sitaxsentan and ambrisentan. A 
recent analysis suggested a lower incidence of adverse events and possibly a 
higher efficacy of sitaxsentan as compared to bosentan, but these findings need to 
be confirmed in an independent study (139).    
The continuous intravenous application of epoprostenol is effective in the treatment 
of Raynaud’s phenomenon secondary to SSc; it decreases the frequency and 
severity of attacks and induces healing of digital ulcers. In a controlled trial, a 
positive effect on exercise capacity and cardiopulmonary hemodynamics has been 
demonstrated (140). Patients with connective tissue-associated pulmonary 
hypertension have also benefited from treatment with sildenafil, a 
phosphodiesterase inhibitor (141). As shown recently, sildenafil also seems to be 
capable to be effective in healing digital ulcers (142). 
 
1.13.3 Immunosuppressive agents  
Up to 60% of SSc patients receive glucocorticoids, although there is no clear 
evidence for its efficacy (143). A significant proportion of SSc patients are treated 
with an immunosuppressive treatment, mostly consisting of cyclophosphamide, 
methotrexate, azathioprine, or hydroxychloroquine. Thus far, clear evidence of 
efficacy exists only for cyclophosphamide, which has been shown to be effective in 
SSc lung disease and skin involvement (144). Unfortunately, the positive effects, 
seem to disappear within one year after treatment cessation (145). Methotrexate is 
widely used in SSc patients with diffuse cutaneous disease. A recent case series 
provided some evidence for its efficacy, with a good response of skin involvement 
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that worsened after withdrawal of the treatment (146). Mycophenolate mofetil 
(MMF) has shown positive effects on SSc-related interstitial lung disease in several 
retrospective studies (147, 148). In addition to its immunosuppressive effect, MMF 
also seems to have an inhibitory effect on TGF-beta. A prospective, Phase I, open-
label study of MMF is currently ongoing (www.clinicaltrials.gov identifier: 
NCT00433186). Another ongoing study is that of treatment with high-dose 
intravenous immunoglobulins (www.clinical trials.gov identifier NCT00348296). 
 
 
1.13.5 TNF-blockage in SSc and other targeted therapy approaches 
In several retrospective case series, TNF-alpha inhibitors showed positive effects 
both on arthritis and skin in SSc (149). Infliximab has been effective in the 
Bleomycin mouse model (118). In a prospective, open-label trial, however, 16 
patients with diffuse SSc who received monthly infliximab infusions showed no 
improvement of the skin score after 26 weeks (135). Abatacept, a recombinant 
fusion protein that blocks T cell activation, has been approved for the treatment of 
RA. A randomized, double-blind, placebo-controlled clinical trial of abatacept 
versus placebo in patients with diffuse SSc is ongoing (www.clinicaltrials.gov 
identifier: NCT00442611) although the current state (from 16.5.2011) is ‘unknown.’  
Rituximab is a monoclonal antibody directed against the CD20 transmembrane 
protein present on B cells (150). Given the potential pathogenetic role of 
autoantibodies, B-cell depletion is also being studied in SSc. In a mouse model of 
SSc, rituximab was found to cause reduction in skin fibrosis, autoantibody titers, 
and hypergammaglobulinemia. However, this positive effect was not observed in 
the chronic phase of the disease. A study in eight patients receiving rituximab 
demonstrated an improvement in the skin score, dermal hyalinised collagen 
content, and numbers of dermal myofibroblasts at 24 weeks (151). A more recent 
study in 15 patients with diffuse cutaneous SSc found no improvement in skin 
fibrosis or autoantibody titer with rituximab treatment, despite efficient B cell 
depletion being demonstrated (152).  
Neutralizing anti-TGF-beta antibodies have been studied in the early diffuse SSc in 
45 patients. The skin score improved both in the investigational and placebo arms, 
but a significant difference was not observed (153). Currently, the p144 peptide 
inhibitor of TGF-beta is being explored for the topical use in SSc 
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(www.clinicaltrial.gov identifier: NCT00574613). The current state of this study 
(date 16.5.2011) also is ‘unknown’.  
 
1.13.6 Antifibrotic agents  
 
Imatinib mesylate  
Imatinib was developed to target the tyrosine kinase ABL which is translocated in 
chronic myelogenous leukemia. In addition to ABL, imatinib also targets other 
kinases such as c-Kit and the PDGF receptor. Tyrosine kinases such as the PDGF 
receptor participate in the activation of fibroblasts. In addition, ABL plays a role in 
the downstream signaling of TGF-beta (154). Data from animal models have 
demonstrated a reduction in fibrosis both in bleomycin-induced lung and skin 
disease as well as in obstructive renal fibrosis after imatinib treatment (155-157). 
Fibrosis also ameliorated in the later stages of SSc (158).  
In five patients with SSc interstitial lung disease treated with 200 mg imatinib per 
day and cyclophosphamide intravenously every 3 weeks, only one patient had an 
improvement in lung function however (159).  
In an ongoing Phase II trial, 18 patients received 400 mg imatinib per day. 
Acceptable tolerability and an improvement of the modified Rodnan Skin Score 
(mRSS) has been shown in an interim analysis (160) albeit no statistical 
significance could be detected. In another report, 15 patient with systemic sclerosis 
have been treated with up to 600 mg imatinib mesylate for one year (161). Over 
two thirds of the patient developed considerable side affects, typically edema, but 
also rash, diarrhea and notably worsening of scleroderma in two patients. In the 
five patients who completed the trial, a slightly improved forced vital capacity and 
skin thickening was observed. 
 
Oral collagen  
Collagen has been identified as a possible autoantigen in SSc. The rationale for 
the oral application of type 1 collagen is the induction of tolerance. In a 
prospective, multicenter trial, 168 patients were treated with 500 mg/day of type 1 
collagen. Although no statistical significance was demonstrated in the primary 
endpoints, the skin status improved significantly in SSc patients with long disease 
duration (162).  
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Roseglitazone  
Rosiglitazone is an agent that has been developed for the treatment of type 2 
diabetes. It is an agonist of the peroxisome proliferator-activated receptor (PPAR). 
PPAR stimulation abrogates collagen expression and TGF-beta-dependent 
myofibroblast differentiation. It has now been demonstrated in the bleomycin 
mouse model that rosiglitazone is effective in reducing skin inflammation and 
dermal fibrosis (163). 
 
Cannabinoid receptor (CB2)  
 CB2 is the receptor for the marijuana component delta9-tetrahydrocannabinol. It 
has been implicated in the regulation of atherosclerosis and is now being 
investigated in SSc. In the bleomycin mouse model, CB2 has clearly shown 
antifibrotic effects (164). Clinical trials in SSc however, have not been carried out 
yet. 
 
1.13.7 Cellular therapy  
Hematopoietic stem cell transplantation (HSCT) in autoimmune diseases is aimed 
at “resetting” the dysregulated immune system by immunoablative therapy followed 
by reinfusion of previously isolated hematopoietic stem cells (165). HSC may 
originate either from the patient him/herself (autologous) or from a human 
leukocyte antigen (HLA)-matched individual, typically a family member 
(allogeneic). Advantages of autologous HSCT are a lower treatment-related 
mortality (TRM) due to the absence of a graft-versus-host disease (GVHD), which 
occurs in 20–40% allogeneic HSCT. On the other hand, a postulated graft-versus-
autoimmunity effect (analogous to a graft-versus-leukemia effect) has been 
suggested for allogeneic HSCT. Prospective, multicenter trials in SSc are currently 
ongoing for autologous HSCT whereas only case reports are available for 
allogeneic HSCT. 
1.13.7.1 Autologous HSCT 
Autologous HSCT is a multistep procedure. Firstly, HSC are mobilized by 
administration of intravenous cyclophosphamide and granulocyte-stimulating factor 
(G-CSF). Stem cells are then collected by leukapheresis. After conditioning with 
high-dose cyclophosphamide, stem cells are reinfused to shorten aplasia and thus 
the risk of bleeding or infection.  
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The main mechanistic effects in autologous HSCT are achieved by eradication of 
autoaggressive “effector T and B cells” and the induction of regulatory T cells. 
There is evidence that autologous HSCT may restore tolerance, despite the use of 
host cells. 
In a French–Dutch collaborative study involving 26 patients for whom long-term 
follow-up data were available, event-free survival, defined as survival without 
mortality, relapse, or progression of SSc resulting in major organ dysfunction, was 
64.3% (95% confidence interval, CI 47.9–86%) at 5 years (166). Skin thickening 
and performance status improved markedly, and organ dysfunction stabilized. 
Similar results have been reported in a North-American study (167). However, 
relapses occurred in one-third of the cases, typically after 2–4 years (166). The 
TRM rate in the autologous setting is approximately 10% (JM van Laar, personal 
communication).  
Currently, there are three prospective, multicenter studies ongoing investigating 
the safety and efficacy of autologous HSCT in SSc. A total of 146 patients have 
thus far been randomized in the European ASTIS (Autologous Stem Cell 
Transplantation International Scleroderma) trial, and accrual is expected to be 
complete by the end of 2009. The two other trials are SCOT (Scleroderma 
Cyclophosphamide or Transplantation Trial) and ASSIST (American Sclerderma 
Stem Cell versus Immune Suppression Trial).  
 
Allogeneic HSCT 
In allogeneic HSCT, stem cells are obtained from matched family members or 
matched unrelated donors. The conditioning regimen includes cytotoxic agents 
such as fludarabine or busulphan and anti-thymocyte globulin with or without total 
body irradiation. The conditioning treatment is mainly performed to allow a 
significant engraftment of the donor stem cells. In order to reduce TRM, non-
myeloablative regimens are increasingly applied. Immunosuppressive therapy with 
methotrexate or cyclosporine is given to prevent GVHD. 
Thus far, the available data are from case series, which demonstrate that 
allogeneic HSCT can lead to a persistent remission or cure of the underlying 
autoimmune disease. Four patients with SSc have been treated with allogeneic 
HSCT to date. The first two, who received myeloablative conditioning, showed 
improvement of skin thickening and resolution of ground glass opacities on chest 
 32 
CT (168). However, one died from a Pseudomonas sepsis 18 months after the 
treatment. Two other patients, who underwent non-myeloablative conditioning, 
remained in full remission for 3 years without signs of GVHD (169, 170). Given the 
lack of available matched donors, the risks associated with allogeneic HSCT, and 
the excellent results with autologous HSCT, it is unlikely that prospective trials of 
allogeneic HSCT will be performed in SSc. 
 
Mesenchymal stem cell transplantation  
MSC are bone marrow-derived stromal cells that give rise to cells such as 
chondrocytes and osteocytes. In addition to their differentiation capacity, MSC 
have immunomodulatory effects and are bystanders in hematopoeisis. A 
therapeutic benefit of MSC transplantation (MSCT) has been shown in GVHD, 
which is considered to share several pathogenic features with SSc (171). Five 
patients suffering from severe, diffuse SSc were elected for this treatment (172). 
MSC were obtained by bone marrow aspiration of cross-gender related donors by 
bone marrow aspiration. Adherent cells were cultured in fresh frozen human 
plasma and platelet lysate. All five patients showed an improvement of their skin 
status and acral ulcers following MSCT. Organ functions stabilized and no 
treatment toxicity occurred. 
 
Pathogenic concept Pathological correlate Possible therapeutical intervention 
Genetic 
Predisposition 
SNP's Downstream targets 
Environmental 
trigger 
unclear, Bleomycine, Gadolinum, 
CMV infection? 
Unclear 
Autoimmunity Adaptive: Autoantibodies, T-cell 
response 
Immunosuppression 
(Glucocorticoids, Cyc, MMF), 
HSCT 
 Innate: unclear, TLR-activation - 
Vasculopathy Vasoconstriction, ischemia/hypoxia, 
endothelial apoptosis,  
Vasodilatation, ET-1 antagonists, 
Prostacyclin, phosphodiesterase 
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Table 3. Pathogenic concepts of SSc and translational interventions. SNP: single nucleotide 
polymorphism, CMV: cytomegalo virus, Cyc: cyclophosphamide, MMF: motil mycophenolate, 
HSCT: human stem cell transplantation, TLR: toll like receptor, ET-1: endothelin 1, CRP: C-reactive 
protein, BSR: blood sedimentation rate, TNF: tumor necrosis factor, TIMP: tissue inhibitor 
metalloproteinase 
ET-1 overexpression inhibitors 
Low grade 
inflammation 
CRP, BSR, TNF-alpha, cellular 
infiltrate 
Immunosuppression, targeted 
therapy, anti-TNF-alpha, anti-IL-6 
Fibrosis TGF-beta production, collagen 
deposition, MMP/ TIMPs 
dysregulation, myofibroblast 
differentiation  
Imatinib, anti-TGF-beta, 
Roseglitazone, collagen 
desensibilitation 
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 CHAPTER 2  
 
 
Tumor necrosis factor (TNF) alpha activated T-cells promote Fibrosis in 
Systemic Sclerosis 
 
 
 
 
2.1 Introduction 
Systemic sclerosis (SSc) is an autoimmune multisystem disease which leads to 
excessive fibrosis of skin and inner organs. It is characterized by vasculopathy and 
persistent low grade inflammation in tissues which ultimately result in an increased 
deposition of extra-cellular matrix by fibroblasts and myofibroblasts (1). Around 
50% of patients with untreated SSc show a prominent inflammatory infiltrate in the 
dermis (2). The inflammatory cell infiltrate mainly consists of lymphocytes, mast 
cells and cells of the monocyte/macrophage lineage (3-6) and the cell infiltrate in 
the dermis correlates with skin thickening (2). Conversely, Langerhans cells in the 
epidermis are reduced in SSc (7). There is growing evidence that the interaction 
between T-cells and fibroblasts influence the expression of extracellular matrix in 
SSc (8). T-cells can also trigger the differentiation of haematolopoietic cells into 
fibrocytes (9) and fibroblast into myofibroblasts, respectively. Myofibroblasts are 
key fibrotic effector cells in SSc and originate from resident fibroblasts or pericytes 
that have migrated into the lesional area (10). Activated T-cells were predominant 
in dermal infiltration in SSc in one study (5) and, interestingly, a recent study 
showed that T-cell transfer from bleomycine treated mice to healthy animals could 
provoke SSc (11). Indeed, imunosuppressive therapy is effective in patients with 
SSc lung fibrosis (12) and lymphoablative treatment with anti thymocyte globulin 
(ATG) followed by autologous heamatopoietic stem cell transplantion (HSCT) has 
been shown to reverse skin thickening and vasculopathy (13). However, these 
treatment regimens are only effective in a subset of patients, presumably related to 
the high heterogeneity of SSc and timing of treatment, respectively. A better 
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understanding both of the cellular and cytokine orchestration of inflammation is 
required to develop more targeted therapies in SSc.  
Tumor necrosis factor (TNF) alpha is a pleiotropic cytokine which is mainly known 
for its proinflammatory properties. It has been successfully targeted in multiple 
inflammatory diseases such as rheumatoid arthritis or spondylarthropathy (14). 
TNF-alpha also has immunosuppressive feedback effects (15, 16) as well as 
profibrotic properties (17). The latter has also been demonstrated in several animal 
models (18). A TNF-mediated cytokine network with TNF-alpha as initiating 
cytokine, triggering other cytokines in chronic inflammatory lesions has been 
discussed (18, 19). The heterogenic effects of TNF might be attributed to two 
different forms of TNF, a membrane bound form and after cleavage, the soluble 
form TNF (sTNF) (20). TNF binds to two different receptors, the TNF-receptor 
(TNF-R)1 (p55) and TNF-R2 (p75). Whereas TNF-R1 is mainly stimulated by 
sTNF, TNF-R2 is also activated by membrane bound TNF, thus dependent on cell 
contact e.g. with macrophages (21-23). TNF-R2 is predominantly expressed on the 
plasma membrane, whereas TNF-R1 largely resides in the trans-Golgi with only a 
small subset of receptors appearing on the cell surface (24). TNF-R1 is 
ubiquitously expressed at a low level. Its activation leads either to apoptosis or NF-
kB dependent gene expression. In contrast, TNF-R2 is preferentially expressed on 
haematoietic and endothelial cells. Both activated lymphocytes and T-regulatory 
cells highly express TNF-R2 (15, 25). Proliferation of peripheral T cells appears to 
be mediated by TNF-R2 costimulation (26, 27). The signalling of TNF-R2 which 
lacks the intracellular death domain, also involves NFkB stimulation and 
costimulates lymphocytes, but further functional effects are less clear. Several 
recent reports have postulated that TNF-R2 is involved in fibrogenesis (17): The 
lack of TNF-R2 prevented the occurrence of fibrosis in the bleomycine mouse 
model (18) and reduced collagen expression in intestinal fibroblasts (17). TNF-R2 
also exhibits anti-inflammatory effects on tolerogenic antigen presenting cells (28).  
It has been demonstrated in animal models lacking the receptorTNF-R2 over-
expression and subsequent shedding by proteases has anti-inflammatory effects 
by binding and inactivating sTNF. Furthermore, prolonged TNF exposure of T-regs 
restore their suppressive influence on T-effector cells (15).  
In SSc, the role of TNF is controversial (29). TNF-receptor knock out mice are 
protected against asbestos induced lung fibrosis (30). In these mice, reduced TGF-
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beta levels have been recognized whereas TNF-alpha levels per se remained 
elevated (30). In antigen presenting cells, TNF-R2 mediates a tolerogenic effect 
(28). As shown by immunohistochemistry (IHC), both TNF-R are over-expressed in 
monocuclear cells in the SSc skin, especially TNF R2 which is expressed on most 
cells (31). The soluble forms of TNF-R1 and R2 are increased in the blood and 
correlate with disease activity (31). Upon direct cell-to-cell contact, lymphocytes 
from SSc patients inhibit collagen expression by fibroblasts via membrane bound 
TNF, an effect that is reduced in SSc fibroblasts (32). On the other hand, T-cells in 
SSc dermis overexpress IL-4, a Th-2 specific profibrotic cytokine. So far, the net 
effect of T-cells on fibroblasts and their differentiation into myofibroblasts is 
unclear. sTNF has been shown to mediate the transition from pulmonary 
inflammation to fibrosis and soluble TNF-alpha expression is a prerequisite for 
TGF-beta expression (33). Experimental models of lung fibrosis respond to TNF 
alpha antagonist (34). In clinical studies, the blockage of TNF with etanercept or 
infliximab has recently been investigated in different SSc cohorts. Etanercept, the 
soluble TNF-R2, was effective in ameliorating SSc-associated arthrtitis and 
reducing skin thickening (35). In another recent study, although not significantly, a 
trent towards improvement of the skin score after treatment with infliximab was 
obersrved; a reduced serum concentration of procollagen could be demonstrated 
and the secretion of collagen by fibroblasts was decreased (36). Possible 
explanations for the stable skin score in this study are that most patients were 
already in a chronic stage where the vascularity and thus drug delivery in the 
tissue is largely impaired. Another reason could be an inhibition of sTNF but not 
membrane bound TNF which has possibly a more important impact on immune 
effector cells in SSc.  
The aim of this study was to identify which mononuclear cells express TNF-R1 and 
-R2 in SSc dermis and to compare their expression levels with disease 
characteristics. We further performed mechanistic studies of the TNF-R on SSc 
lymphocytes and investigated a potential pro-fibrotic effect upon their stimulation. 
Finally we tested our hypothesis in patients who underwent lymphoablative 
treatment followed by heamatopoietic stem cell transplantation.  
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2.2 METHODS 
 
Patient recruitment 
Patients with SSc were recruited from the Freeman hospital in Newcastle or the 
James Cook University Hospital in Middlesbrough, U.K. Ethical approval and 
written consent was obtained (REC number: 09/H0905/11). All patients were 18 
years or older and fulfilled the ACR criteria for SSc according to LeRoy (37). 13 
patients were included in this study, 8 had diffuse SSc and 5 limited SSc. One 
patient with diffuse SSc who received autologous haematopoietic stem cell 
transplantation (HSCT) underwent two skin biopsies, one before and one six 
months after HSCT. The exact treatment proceedure of HSCT is explained 
elsewhere. Additional 19 skin biopsies from a Dutch SSc cohort in Leiden served 
as a control group and were analysed by IHC. Healthy skin samples were obtained 
from breast of patients undergoing breast reduction surgery. 
 
Flow cytometry of skin 
The multicolour flow cytometry technique of skin cells has been adapted from the 
group of Prof . M. Collin, Institute of Cellular Medicine, Newcastle University (38). 
After informed consent was obtained, a 4 mm punch biopsy from the dorsal side of 
the forearm of SSc patients was performed in 13 patients under local anaesthesia 
(1% Lidocain). One patient underwent a second biopsy after haematopoietic stem 
cell transplantation. The skin was digested with 10 U/ml dispase (Gibco BRL) for 1 
hour in Exvivo medium. The epidermis was removed with a scalpel and the dermis 
was digested in 1.6 mg/ml collagenase type 4 (Worthington’s) overnight in Exvivo 
medium. Cells were re-suspended and blocked with 1% mouse IgG (Sigma) for 10 
minutes at 4°C. Cells were stained with labelled an tibodies for CD45, HLA-DR, 
CD14, CD16, CD1a, CD3, CD4, CD19 (all Becton Dickinson) and TNF-1 and -2 
(R&D systems), respectively (see table 1) on ice for 1h. Multicolour flow cytometry 
with prior adequate compensation procedures were performed using a BD LSRII 
cytometer and the FACS Diva software. Macrophages are identified and excluded 
from the analysis on the basis of autofluorescence at 488/610 nm.  
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Figure 1. Schematic illustration of flow cytometry of the skin. 4 mm punch biopsies from the 
forearm were digested with dispase for 1 hour to remove the epidermis and overnight in 
collagenase. Then, cells were resuspended and stained for flow cytometry. Leukocytes were 
identified by CD45+ cells (centre) and include macrophages, monocytes, dendritic cells, Langerhans 
cells, mast cells and lymphocytes. Autofluorescence (AF) was recorded in the FL1 channel (488-nm 
laser and 530/30 band-pass). In a ‘dendritic cell panel’ (on the right), cells were stained with CD45 
APC-H7, CD14 Horizon blue, CD16 PE Cy7 and CD1a APC. CD45+ cells were devided into HLA-
DR+ which represent antigen presenting cells and HLA-DR- SSClow which are lymphocytes and 
HLA-DR-SSChigh mast cells. Macrophages were identified by their AF. CD1a+ dendritic cells and 
CD14+ monocytes were identified on HLA-DR+AF- cells. Langerhans cells were identified as 
CD45+HLA-DR+AF-CD1abright .  
In a ‘lymphocyte panel’ (on the left) we stained with CD45 Pacific orange, HLA-DR PerCP Cy.5, 
CD4 PE-Cy7, CD8 APC, CD3 V450 and APC-H7. CD45+SSClow cells were selected to identify T- 
(CD3) and B-(CD19) cells. CD3+ cells were assessed for CD4 and CD8 expression. Backgating of 
CD3+ cells corresponded to the CD45+HLA-DR-SSClow cells from the ‘dendritic cell’ panel.  
 
 
Flow cytometry of peripheral blood 
Most antibodies used for blood flow cytometry correspond to those used for the 
skin. CD11c was used instead of CD1a for dendritic cell staining. Antibodies were 
added to 100 µl whole blood for 1 hour and incubated on ice. Red cells were lysed 
subsequently with BD Lysis Buffer and washed in buffer.    
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Antibody Fluorochrome 
HLA PerCP Cy5 (5µl) 
CD45 APC-H7 (5µl),Pacific orange (5µl) 
CD14 Horizon blue (5µl) Qdot605 (1µl) 
CD16 PE Cy7 (5µl) 
CD1a APC (5µl) 
CD3 FITC (5µl),PE (5µl) V450 (5µl) 
CD19 FITC (5µl) PE (5µl), APC-H7 (5µl) 
TNF-R1 FITC(2.5µl) (Isotype 0.25 µl) 
TNF-R2 PE (10µl) (Isotype 10 µl) 
 
Table 1. Antibodies for skin flow cytometry.  
 
 
Antibody Fluorochrome 
HLA PerCP Cy5 (5µl) 
CD45 APC-H7 (5µl) 
CD14 Q-dot 605 (1µl) 
CD16 PE Cy7 (5µl) 
CD11c APC(5µl) 
Linage FITC (CD3,19,56 each 5µl)/ PE (CD3,19,56 each 5µl) 
TNF-R1 FITC (2.5µl) (Isotype 0.25 µl) 
TNF-R2 PE (10 µl) (Isotype 10 µl) 
 
Table 2. Antibodies for blood flow cytometry.  
 
CD3 cell isolation 
40 ml whole blood was collected during standard outpatient procedures in EDTA 
containing tubes (BD Bioscience). The samples were processed within four hours 
of collection. Peripheral blood mononuclear cells (PBMC) were separated from 
whole blood by ficoll-hypaque density gradient centrifugation (Axis-shield PoC AS, 
Oslo, Norway). CD3+ lymphocytes were isolated from total PBMC according to the 
manufacturer’s protocol with the CD3+ MACS beads isolation kit (Miltenyi biotec 
GmbH Bergisch Gladbach, Germany) described in detail elsewhere (39). In short, 
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40x106 PBMC were suspended in PBS supplemented with 1% foetal-calf serum 
(Sigma-Aldrich) and EDTA (2mM) plus 40 µl of anti-CD3+ Miltenyi magnetic beads 
on ice for 20 minutes. Total mixture was past through a magnetic isolation column 
(Miltenyi Biotec). Purified CD3+ monocytes were removed from the column and 
tested for purity by flow cytometry. Flow cytometric analyses showed a >95% 
purity for CD3+ cells. Cells were then cultured in Dulbecco medium (DMEM) 
containing 10% fetal calf serum and 2mM glutamine, 100 U/ml penicillin and 100 
µg/ml streptomycin in an incubator at 37°C containi ng 5% CO2. 
 
   
TNF-R stimulation and T-cell activation by CD3/28 beads 
CysTNF mutations are selective agonists for TNF-R1 or –R2 (table 2) and the 
physiological soluble TNF (sTNF) stimulate mainly TNF-R1 and probably to a 
minor extend also TNF-R2. The latter is controversial and currently being 
investigated by A. Krippner-Heidenreich (personal communication).  
CysTNF mutants were added to 1 x 106 CD3+ cells (isolated from peripheral blood, 
according to methods above) and cultured in DMEM containing 10% fetal calf 
serum and 2mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. 
CysTNF concentrations were titrated from 10 ng/ml to 100 ng/ml and cells were 
incubated from 4h to 48h. IL-6 expression was most prevalent after stimulation of 
the lymphocytes at a concentration of 100 ng/ml cysTNF for 24h. Cells were then 
harvested and processed for expression analysis as described below (Fig. 2). 
In a second set of experiments, CD3+ lymphocytes were identically isolated and 
cultured in the same medium in presence of CD3/28 T-cell expander Dynabeads 
(Invitrogen) at a 1:1 bead T cell ratio for 24h. Then, cysTNF mutants were added in 
the same concentration for further 24h before cells were harvested.   
 
Ligand / mutation Effect 
CysTNF 32W/86T (stock 1 mg/ml) Stimulation of TNF-R1 
CysTNF 193N (stock 0.9 mg/ml) Stimulation of TNF-R2 
Soluble TNF (stock 0.5 mg/ml) Stimulation of TNF-R1, possibly –R2 
 
Table 3. Agonists for TNF-receptors.    
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1 x 106 CD3+ cells
1:1 CD3/28 beads + 100 ng/ml cysTNF-R1,-R2 or sTNF
24h 24h
Harvest
SN for MSD/CBA analysis
RNA isolation for RT-PCR
+ 100 ng/ml cysTNF-R1,-R2 or sTNF
Harvest
 
 
Figure 2. Schematic illustration of lymphocytes by cysTNF with or without prior treatment with 
CD3/28 activation beads. R1= receptor 1, R2= receptor 2. SN: supernatant 
 
Gene expression 
RNA from CD3+ T-lymphocytes was isolated using the RNA mini kit from Qiagen 
according to the manufacturer’s protocol. The RNA concentration was measured 
by Nanodrop 1000. 200-750ng of RNA was treated with DNAse for 30 minutes at 
37°C then reverse transcribed to cDNA using random hexamers (Invitrogen) and 
moloney murine leukaemia virus reverse transcriptase (MMLV-RT) enzyme 
(Invitrogen) according to the manufacturer’s protocol. 20ng of cDNA, 1µl of 30µM 
forward primer and 1µl of 30µM reverse primer, 0.2µl of 100µM probe and 0.2µl of 
reference dye. Taqready master mix (Sigma) was used to analyse expression. 
Samples were analysed in triplicate and normalised to the housekeeping gene 
(18S) using AB7500 (applied biosystems) qPCR machine and program. Relative 
expression to the housekeeping gene was calculated using: (2∆∆cycle time) -1. The 
primers used for IL-6 were: forward primer 5’- TACCCCCAGGAGAAGATT -3’, 
reverse primer 5’- AAGGTTCAGGTTGTTTTC -3’, probe 7 from universal probe 
library (Roche Applied Science). 
Primers and probe for IL-10: forward primers 5’- GGTGATGCCCCAAGCTGA -3’, 
reverse primer 5’- GCCTTGCTCTTGTTTTCA -3’ and probe 65 from universal 
probe library (Roche Applied Science). Primers and probes for TGF-beta: forward 
primer: 5’- TGACAGCAGGGATAACACACT -3’, reverse primer 5’- 
GCCGCACGCAGCAGTTCTTCT -3’ and probe 68 from the universal probe library 
(Roche Applied Science). Primers and probe for 18S: forward primer 5’- 
CGAATGGCTCATTAAATCAGTTATGG -3’, reverse primer 5’- 
TATTAGCTCTAGAATTACCACAGTTATCC -3’ and probe 5’-FAM- 
TCCTTTGGTCGCTCGCTCCTC –TAMRA-3’. Primers and 18S probe were from 
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Sigma-aldrich. qPCR settings were applied according to Taqready mix 
manufacturers protocol. 
 
 
ELISA 
The custom MSD protocol was applied. 25µl HSC Assay Diluent were added to 
each well and incubated for 30 minutes with shaking (300-1000rpm) at room 
temperature. 25µl of calibrator or sample were added to each of the necessary 
wells. The plate was sealed with adhesive film and incubated for 2 hours with 
shaking (300-1000rpm) at room temperature. The plates were washed 3x with 
MSD wash (DPBS with Tween-20 at 0.05%) then 25µl of Detection Antibody 
Solution was added per well. The plate was sealed with adhesive film and 
incubated for 1-2 hours with shaking (300-1000rpm) at room temperature. Wells 
were washed 3x with MSD wash then 150µl of Read Buffer T 2X were added to 
each well. 
 
Western blotting 
Supernatants were removed before cell lysis with the lysis buffer (20mM Tris 
pH7.5, 1mM EDTA, 100mM NaCl, 1% Triton X-100, 0.5% DOC, 0.1% SDS 
1XPIT complete protease-inhibitor cocktail (Roche Diagnostics). This was then 
spun to remove cell debris (4˚C for 10 minutes 15000 RPM). 4X SDS sample 
buffer (125 mM Tris pH6.8, 20% Glycerol, 6% SDS, 0.02% Bromphenolblue, 10% 
β Mercaptoethanol)  was diluted to a 1X concentration and added then the sample 
was cooked (95˚C for 5minutes). Samples were run through a 6.5% acrylamide gel 
with a 4.5% acrylamide stacking gel, the gel was run at 50V until sample was in 
second gel then at 150V until the end of the run. Gel was in gel chamber filled with 
SDS buffer (25 mM Tris pH 8.3, 192mM Glycine and 0.1% SDS). Membranes  
were soaked in methanol prior to tank blotting. Blotting chamber was built as: fibre 
pad, whatman filter sheet, acrylamide gel, whatman filter sheet, fibre pad. Blotting 
chamber soaked in western blotting buffer (25 mM Tris pH 8.3, 192mM Glycine, 
20% Methanol) and placed in running chamber filled with cold western blotting 
buffer and an icepack. Transfer ran for 3 hours at 100mA (for 2 gels). 
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Unspecific binding sites on the membrane were blocked by incubating overnight in 
cold room with 5% low fat milk in TBS-T (50mM Tris pH 7.6, 150mM NaCl, 0.1% 
Tween 20). Alpha SMA antibody was diluted 1:1000 in 5% milk with TBS-T, alpha 
SMA antibody used was Mouse Anti Human Actin [alpha smooth muscle actin 
isoform] monoclonal antibody (Millipore). Membrane was incubated with primary 
antibody (alpha SMA) for 1 hour at room temperature. The membrane was washed 
three times with TBS-T before incubation for 1 hour at room temperature with a 
secondary antibody (Polyclonal Goat anti mouse immunoglobulins/ HRP (Dako) 
diluted 1:20000 in 5% milk with TBS-T). The membrane was then washed a further 
three times with TBS-T. Millipore Immobilon ™ western chemiluminescent HRP 
substrate kit used for detection as the manufacturer’s protocol. Membrane were 
developed on an x-ray film.  
Membrane was then stripped by incubating at 50˚C for 25 minutes with a stripping 
buffer (Tris-HCL: 7.8grams Tris in 1000ml dH20, pH to 6.0, 2% SDS (20g SDS in 
the 1L) with 331µl β-mercaptoethanol added fresh for 50ml). The membrane was 
then ready to block again for incubation with Collagen or GAPDH. Primary 
antibody for collagen: Rabbit anti-human type 1 polycolnal antibody (chemicon 
international) diluted 1:200 in 5% milk with TBS-T. Secondary antibody for 
collagen: Polyclonal Goat anti Rabbit Immunoglobulins/HRP (Dako) diluted 
1:20000 in 5% milk with TBS-T. Primary antibody for GAPDH: Monoclonal mouse 
anti rabbit glyceraldehyde-3-phosphate dehydrogenase (HY-Test) diluted 1:500 in 
5% milk with TBS-T. Secondary antibody for GAPDH: Polyclonal Goat anti mouse 
immunoglobulins/ HRP (Dako) diluted 1:20000 in 5% milk with TBS-T.  
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Patient Age Sex Subtype Disease duration since first 
onset of non-Raynaud 
Comorbidity Autoantibody status mRSS Immunosuppressive 
treatment 
1 62 M Diffuse 2 Mantle cell lymphoma neg. 25 none 
2 58 W Diffuse 2  ANA 30 Cyclophosphamid 
3 45 W Diffuse 3 Lymphoma, vasculitis, 
chronic renal failure 
neg. 35 Steroids 
4 75 M Limited 35  neg. 6 None 
5 60 W Limited 18  neg. 10 Cyclophosphamid 
6 65 W Diffuse 4  Scl-70 13 Cyclophosphamid 
7 65 W Diffuse 3  ANA, anti-RNA 28 MMF 
8 75 W Limited 8  anti-centromer 4 none 
9 76 M Diffuse 5 Asbestos Scl-70 35 Cyclophosphamid 
10 49 W Limited 12 RA overlap ANA 9 none 
11 48 W Limited 4  ANA 4 none 
12 50 W Diffuse 3  neg. 30 MTX, Steroids 
13 62 M Diffuse 2  Scl-70 32 Cyclophosphamid 
 
Table 4. Clinical characteristics of SSc patients in which skin biopsies were performed at their forearms. 
 61 
2.3 RESULTS 
 
 
Identification of leukocyte subsets in the dermis of SSc patients by flow 
cytometry.  
Skin samples of involved skin from the forearm of 13 SSc patients and from the 
breast of 1 healthy individual undergoing breast reduction surgery were obtained. 8 
patients were classified as diffuse SSc, 5 patients had limited SSc. Figure 3A 
shows the gating strategy in two representative patients with diffuse and limited 
SSc and the healthy control. Dermal leukocytes were identified as CD45+ cells 
within the live cell gate (not shown). CD45+ cells were subsequently divided into 
HLA-DR+ antigen presenting cells, HLA-DR-SSChigh mast cells and HLA-DR-SSClow 
lymphocytes according to previous studies (38). Macrophages were identified by 
autofluoresence as CD45+HLA-DR+AF+ cells. CD1a+ and CD14+ cells were gated 
out of the CD45+HLA-DR+AF- cell subset. Langerhans cells were identified as 
CD45+HLA-DR+AF-CD1abright.  
A higher percentage of dermal leukocytes per live cells were observed in skin from 
diffuse SSc patients (23.9% range 14.4-65.6) compared to limited SSc patients 
(9.8% range 5.4-17.3; p=0.03) (Figure 3B). Leukocytes of SSc patients were lower 
compared to skin from the healthy control, suggsting a higher number of stromal 
cells in SSc dermis. HLA-DR-SSClow lymphocytes also were significantly higher in 
patients with diffuse SSc (46.6%, range 32.2-53.0; vs. 28.7%, range 17.8-37.9; 
p=0.03). Mast cells infiltration did not differ between groups (21.7% range 16.1-
42.4 vs. 24.5% range 10.7-44.0; p=0.75) but was higher compared to the control. 
No significant difference was found in CD1a+ cell percentages between limited 
(4.1%, range 0.9-5.9) vs. diffuse SSc (1.0%, range 0.5-1.6; p=0.09) and CD14+ 
cells (0.6%; range 0.1-1.3 vs. 0.7%, range 0.3-1.4; p=0.66). CD1a+ cell numbers 
were higher and CD14+ cells were lower than in the healthy control. Macrophages 
were significantly more prevalent in limited SSc patients (21.0%, range 16.2-31.4 
vs. 11.3%, range 8.5-14.3; p=0.007) and higher than in healthy control. 
Lymphocyte subsets were analysed by flow cytometry in two patients with limited 
and diffuse SSc, respectively (Figure 3C). CD45+SSClow cells were selected to 
identify T- (CD3+) and B-(CD19+) cells. CD3+ cells were assessed for CD4 and 
CD8 expression. Back-gating of CD3+ cells corresponded to the CD45+HLA-DR-
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SSClow cells from the previous experiments. Of CD45+CD3+ cells CD4+ positivity 
ranged from 56.8% to 65.0% and CD8 positivity from 35.0-40.2%. Only 1-5% of 
CD3 cells were CD4CD8 double positive. The patient with diffuse SSc had a higher 
percentage of CD3+ cells. In this patient CD4+ cells were predominant (67.7%) 
compared to CD8+ cells (26%). B-cell percentage per CD45+ cells in this patient 
was relatively low with 2.1%. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Flow cytometry of skin in SSc patients. 4 mm punch biopsies from the forearm of 13 SSc 
patients were digested with dispase for 1 hour to remove the epidermis and subsequently over 
night in collagenase. Cells were resuspended and stained for flow cytometry. Leukocytes were 
identified by CD45+ cells and include macrophages, DC, mast cells and lymphocytes. 
Autofluorescence (AF) was recorded in the FL1 channel (488-nm laser and 530/30 band-pass). 
A: In a ‘dendritic cell panel’, cells were stained with CD45 APC-H7, CD14 Horizon blue, CD16 PE 
Cy7 and CD1a APC. CD45+ cells were devided into HLA-DR+ which represent antigen presenting 
cells and HLA-DR- SSClow which are lymphocytes and HLA-DR-SSChigh which are mast cells. For 
the further gating strategy, CD1a+ and CD14+ cells were identified on HLA-DR+ and AF negative 
cells. Langerhans cells were identified as CD45+HLA-DR+AF-CD1abright . B: Leukocyte subset 
percentages per CD45+ cells were compared between patients with limited versus diffuse SSc and 
one healthy control. Significant differences were found in lymphocytes which were higher in diffuse 
SSc patients. Conversely, macrophages were significantly more prevalent in patients with limited 
SSc. C: Skin of three patients was stained in a ‘lymphocyte panel’ which included CD45 Pacific 
orange, HLA-DR PerCP Cy.5, CD4 PE-Cy7, CD8 APC, CD3 V450 and APC-H7. CD45+SSClow cells 
were selected to identify T- (CD3) and B-(CD19) cells. CD3+ cells were assessed for CD4 and CD8 
expression. Backgating of CD3+ cells corresponded to the CD45+HLA-DR-SSClow cells from the 
previous experiments. Of CD45+CD3+cells CD4+ positivity ranged from 56.8% to 65.0% and CD8 
positivity from 35.0-40.2%. Only 1-5% of CD3+ cells were double positive for CD4 and CD8.  
D: CD45+ cells, CD45+HLA-DR-SSClow lymphocytes, CD45+HLA-DR+AF-CD1a+ dendritic cells, 
CD45+HLA-DR+AF-CD1abright Langerhans cells, CD45+HLA-DR-SSChigh mast cells and CD45+HLA-
DR+AF-CD14+ monocytes were quantified as percentage of CD45+ cells. Percentages of cell 
subsets were correlated with the modified Rodnan Skin Score (mRSS) which assesses the skin 
thickening in SSc. A positive correlation between skin thickening and lymphocytes and a negative 
correlation with CD1a+ and macrophages was seen. In contrast, no correlation with skin thickening 
could be detected for mast cells or CD14+ monocytes.  
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Lymphocyte infiltration positively correlates, whilst macrophage infiltration 
negatively correlates with skin thickening.  
The number of CD45+ cells per live cells increased with skin thickening (measured 
as mRSS) (p=0.08) (Figure 3D). CD45+HLA-DR-SSClow lymphocyte infiltration 
significantly correlated with mRSS (p=0.04). There was no correlation of mast cells 
and CD14+ percentages with skin thickening but both macrophages (p=0.04) and 
CD1a+ (p=0.05) cells negatively correlated with skin thickening and were more 
prevalent in patients with limited SSc. The number of Langerhans cells in the 
dermis did not correlate with skin thickening. CD1a+ Langerhans cell number in the 
epidermis was assessed by IHC. Numbers per visual field were lower in patients 
with diffuse SSc, compared to patients with limited SS or healthy control skin, 
respectively (data not shown).  
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These results were confirmed by IHC where we found significantly more CD3+ T-
cells in patients with diffuse SSc but lower numbers of CD1a+ and CD14+ cells as 
compared to patients with limited SSc (Figure 4A). Mast cell infiltration identified by 
toluidine blue staining did not depend on the subtype but was higher in patients 
with recent onset of non-Raynaud phenomenon symptoms (see mast cell chapter). 
High numbers of lymphocytes in the dermis of patients with diffuse SSc was 
confirmed by electron microscopy (Figure 4B). 
 
 
 
CD14
CD1a
CD3
A B
Normal Diffuse SScLimited SSc
*
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Figure 4. Inflammatory cell subsets in SSc dermis assessed by immunohistochemistry and electron 
microscopy. Higher numbers of CD14+ and CD1a+ cells were found in the dermis of patients with 
limited SSc whereas lymphocytes were more prevalent in diffuse SSc (Figure 4A). Electron 
microscopy (Figure 4B) of the dermis of a patient with diffuse SSc confirms the high number of 
lymphocytes (black arrowheads), mast cells (black arrows) and antigen presenting cells (white 
arrowheads). Blood vessels are indicated by asterisks. 
 
 
 
TNF-receptor expression of dermal leukocyte subsets and in peripheral 
blood. 
TNF-R 1 and 2 expression was analyzed by flow cytometry on CD45+HLA-DR-
SSClow lymphocytes, CD45+HLA-DR+AF+ macrophages, CD45+HLA-DR+AF-CD14+ 
cells and CD45+HLA-DR+AF-CD1a+ dendritic cells (Fig. 5A). Both TNF-R1 and- R2 
expression was predominant on lymphocytes. To a minor extent, TNF-R1 was also 
expressed on CD14+ and CD1a+ cells. On lymphocytes, TNF-R2 expression 
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measured by mean intensity fluorescence (MIF) compared to isotype controls on 
lymphocytes was 1.8 fold, whereas MIF of TNF-R1 expression only was 1.1 fold 
compared to the isotype control (Fig. 5B). TNF-R2 but not TNF-R1 expression 
correlated significantly with skin thickening (p=0.02) (Fig. 5C). The three patients 
with the highest skin scores and progressive disease course showed the highest 
TNF-R2 expression on dermal lymphocytes. 
TNF-R expression on lymphocyte subsets was confirmed by concomitant staining 
with CD3, CD4 and CD8 in two SSc patients. In the patient with diffuse SSc, TNF-
R2 was expressed on CD4+ and CD8+ subsets. In contrast, TNF-R1 was not or 
slightly expressed (Fig. 5D).  
We also analyzed TNF-R expression on lymphocytes in peripheral blood in 11 
patients, 4 of those also had received skin biopsies. TNF-R2 was significantly 
upregulated in SSc patients compared to healthy controls, whereas no expression 
of TNF-R1 could be detected (Figure 5C). In the 4 patients with concomitant skin 
and blood analysis, we found an upregulation of TNF-R2 both in skin and in blood. 
The patient with the highest TNF-R2 expression pattern had the highest mRRS, a 
progressive disease course and did not receive prior cyclophosphamid treatment. 
 
 
 
 
 
 
 
 
 
 
Figure 5. TNF-R1 and R2 expression in SSc skin and peripheral blood. Dermis of 13 SSc 
patients was processed and stainded as described in material and methods. FITC-labeled TNF-R1 
and PE-labeled TNF-R2 antiserum was added to the antibody panel. TNF-R1 and –R2 expression 
was evaluated in SSc patients and a healthy control on macrophages, CD1a+ dendritic cells, CD14+ 
monocytes and lymphocytes. Both TNF-R1 and -R2 expression was most distinctively expressed 
on lymphocytes; to a minor extent, TNF-R1 was also expressed on CD1a+ dendritic cells and 
CD14+ monocytes (Fig. 5A). TNF-R2 was significantly higher expressed on SSc patients with a 
diffuse disease subset, whereas TNF-R1 expression (which is mainly intracellular) was lower and 
had been detected only in a few patients (Figure 5B). In contrast to TNF-R1, TNF-R2 expression 
did correlate with skin thickening (Fig. 5C). Analysis of T-cell subsets revealed that TNF-R1 and R2 
were expressed on CD3, CD4 and CD8 positive cells (5D).  
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Figure 6. TNF-R2 was significantly upregulated on lymphocytes TNF-R expression on lymphocytes 
in peripheral blood from 11 SSc patients and healthy controls. from SSc patients compared to 
healthy controls. TNF-R1 was not upregulated. 
 
 
 
SSc lymphocytes overexpress IL-6 and TGF-beta upon selective TNF-
receptor stimulation, but their IL-10 expression is impaired. 
CD3+ cells were isolated from peripheral blood of 8 diffuse SSc patients from the 
same patient pool receiving skin biopsies and 8 healthy controls by Ficoll and 
magnetic beads as described in the methods section. 1x106 cells were 
subsequently stimulated for 24h with 100 ng/ml selective TNF-alpha mutants: 
cysTNF-R1 selectively stimulates TNF-R1 whereas cysTNF-R2 selectively 
stimulates TNF-R2. Soluble TNF (sTNF) stimulates predominantly TNF-R1 and to 
a minor extent TNF-R2. Both resting T-cells and priorly CD3/28 activated cells 
were analyzed. In resting T-cells, IL-6 expression of cultured lymphocytes from 
SSc patients was higher than in control lymphocytes (Figure 7A). Notably 
stimulation with CysTNF-R1 led to a higher IL-6 expression in SSc lymphocytes. 
IL-10 expression was detected after CD3/28 activation (7B). IL-10 mainly 
increased after costimulation of TNF-R2. Conversely, costimulation of SSc 
lymphocytes with TNF agonists did not lead to IL-10 upregulation as seen in 
normal lymphocytes. This might indicate that lymphocytes of SSc patients lack a 
regulatory potential upon TNF-stimulation and therefore the resolution of 
inflammation might be impaired. Stimulation of TNF-R2 led to a higher TGF-beta 
expression SSc lymphocytes (7C). 
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Figure 7. Cytokine expression of SSc lymphocytes after co-stimulation with TNF agonists. CD3+ 
cells were isolated from peripheral blood of 8 diffuse SSc patients by magnetic beads and cultured 
in DMEM + 10% fetal calf serum. 100 ng/ml of selective TNF mutants CysTNF-RI and CysTNF-R2 
or soluble TNF were added to the cells for 24 hours. In resting T-cells, IL-6 expression of SSc 
lymphocytes was higher than in control lymphocytes (7A), notably upon stimulation of TNF-RI. 
Stimulation of TNF-R2 led to a higher TGF-beta expression SSc lymphocytes (7C). After stimulation 
with CD3/28 beads (activated), IL-10 expression as observed in healthy lymphocytes after 
stimulation of TNF-R2 was impaired in SSc lymphocytes (7B). 
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CD-3+ lymphocyte correlate with alpha-SMA+ myofibroblast infiltration in SSc 
dermis  
A possible correlation between CD3+ T-cells or CD20+ B-cells and myofibroblasts 
was investigated in an independent patient cohort of 18 patients by IHC. Skin 
biopsies were obtained from affected and unaffected skin. In accordance to our 
flow cytometry results CD3+ cell infiltration of affected skin was higher in patients 
with diffuse SSc compared to limited SSc (p=0.03)(Figure 8 and 9). CD3+ infiltrates 
were mainly found in affected SSc skin (Figure 10). However, low grade CD3+ cell 
infiltration was also prevalent in unaffected skin. Higher infiltrates of alpha-SMA 
positive cells are observed only in affected skin. Conversely, no alpha-SMA 
positive cells were seen in the most samples of unaffected skin. For quantification, 
cell infiltrates were blindly scored from 0-3. 3 was regarded as high, 2 as 
intermediate, 1 as low and 0 as no cell infiltration. We found a weak but significant 
correlation between CD3 cells (p=0.038, r2=0.24) and CD20+ cells (p=0.0041, 
r2=0.24) and alpha-SMA positive cells in affected SSc skin (Figure 11). 
 
 
 
 
 
Figure 8. Immunohistochemistry of CD3+ and alpha-smooth muscle actin (αSMA) 
cells in skin of a healthy individual and patients with limited or diffuse SSc. Single CD3+ cells are 
seen in normal skin. In limited small accumulation of T-cells are seen, whereas abundant cell 
infiltrates are observed in diffuse SSc. A similar pattern is seen for αSMA expressing pericytes and 
myofibroblasts. 
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Figure 9. Dermal CD3+ cells quantified in immunohistochemistry are higher in patients with diffuse 
vs. limited SSc. Postive cell infiltrates were scored from 0-3 in an independent dutch cohort of 18 
SSc patients. 3 was regarded as high infiltration, 2 as intermediate, 1 as low and 0 as no cell 
infiltration. Similar to the flow cytometry data, CD3+ infiltrates were higher in diffuse SSc patients. 
 
A 
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Figure 10. CD-3 lymphocyte and alpha-SMA+ cell infiltration assessed by immunohistochemistry 
from affected or unaffected sites in SSc patients.  
Postive cell infiltrates were scored from 0-3 in an independent dutch cohort of 19 SSc patients. 3 
was regarded as high infiltrate, 2 intermediate, 1 were low and 0 no positive CD3 cells. CD3 
infiltrates were mainly found in affected SSc skin. Low grade infiltration is also prevalent in 
unaffected skin. In contrast, no alpha-SMA positive cells are seen in the most samples of 
unaffected skin. Higher infiltrates of alpha-SMA positive cells are observed only in affected skin.  
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Figure 11. CD3 T-cell and B-cell infiltration correlate with myofibroblast infiltration in dermis of SSc 
patients. Skin biopsies were obtained in 18 patients with SSc. CD3+ T-cells and alpha-SMA+ 
myofibroblasts were identified by IHC. Cell infiltration was scored blinded from 0= no infiltration, 1 = 
low infiltration, 2= intermediate and 3=high infiltration. There was a significant correlation both 
between CD3+ (p=0.038, r2=0.24) and CD20+ (p=0.0041, r2=0.24) cells and myofibroblast infiltration. 
 
 
 
Conditioned media of TNF-activated lymphocytes from four SSc patients 
promote alpha-SMA expression by healthy or SSc fibroblasts.  
CD3+ lymphocytes from four SSc patients and four healthy controls were isolated 
by positive selection using magnetic beads as described above and stimulated in 
independent experiments for 24h with CysTNF-R1, R2, sTNF or no TNF. Healthy 
or SSc fibroblasts were then incubated with the conditioned media for further 24h 
and alpha-SMA expression detected by Western blotting (Fig. 12). Compared to 
healthy lymphocytes, conditioned medium from TNF naive SSc lymphocytes had 
an inhibitory effect on alpha-SMA expression. In contrast to healthy lymphocytes, 
supernatant of CysTNF-R1, R2 or sTNF stimulated lymphocytes restored the 
induction of alpha-SMA expression. This shows that resting SSc T-cells might be 
profibrotic towards healthy fibroblasts after TNF-R1, R2 or sTNF costimulation. The 
inhibitory effect of unstimulated lymphocytes is abolished in fibroblasts from SSc 
patients. 
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Figure 12. Effect of conditioned media of TNF-stimulated lymphocytes on alpha-SMA expression 
by healthy or SSc fibroblasts. Supernatant (SN) of unstimulated SSc lymphocytes inhibit alpha-
SMA expression in healthy fibroblasts but not in SSc fibroblasts. In contrast to healthy lymphocytes, 
TNF stimulation of SSc lymphocytes restores the induction of alpha-SMA expression.  
 
 
Dermal CD3+ T-cell and myofibroblast infiltration is reversible after HSCT. 
CD3+ cells and myfibroblast infiltration was assessed in a patient with diffuse SSc 
pre- and 6 months post HSCT. Skin thickening has improved partly in this patient; 
skin biopsies were taken from the same localisation at the forearm. CD3+ T-cell 
infiltration and alpha-SMA positive myofibroblast infiltration was assessed by IHC, 
showing a clear reduction both of CD3+ lymphocytes and myofibroblasts (Fig. 13).  
 
TNF-receptor overexpression is reversible after HSCT. We measured dermal 
TNF-R1 and R2 expression by flow cytometry in correspondence to previous 
experiments. In this patient, we found a complete downregulation of TNF-R1 and 
R2 six months post HSCT (Fig. 14).  
Protracted lymphopenia in peripheral blood after HSCT. Similar to the 
observations in SSc dermis of the patient 6 months after HSCT, we also found a 
protracted lymphopenia, notably of CD4+ helper cells. In contrast, T-supressor 
cells and NK-cells were increased after HSCT (Fig. 15). 
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Figure 13. CD3 and alpha-SMA expression in skin from a patient with diffuse SSc before and 6 
months after autologous haematopoietic stem cell transplantation (HSCT). Skin biopsies from the 
forearm were obtained and stained with hematoxilin/eosin or with CD3 or alpha-SMA. The cellular 
infiltrate before transplant has widely reduced after the procedure. Abundant CD3+ cells are seen 
before HSCT, whereas only single CD3 positive cells are found after. The same is the case for 
alpha-SMA positive cells. 
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Figure 14. TNF-R up-regulation on lymphocytes reverses after autologous HSCT. Skin from the 
forearm of a patient with diffuse SSc who underwent autologous HSCT was digested with dispase 
and collagenase and prepared for flow cytometry. Lymphocytes were identified as CD45+HLA-
DR+AF- SSClow cells. TNF-R were stained with FITC (TNF-R1) or PE (TNF-R2). After the ‘reset’ of 
HSCT, lymphocytes loose their activation. 
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Pre 
HSCT 
absolute 
count (%)
Post 
HSCT 
absolute 
count (%)
Peripheral blood:
T Lymphocytes 
(CD3+)
768 (74) 189 (26)
T Suppressor
Lymphocytes 
(CD3+CD8+)
114 (12) 125 (18)
T-helper 
Lymphocytes 
(CD3+CD4+)
607 (62) 61 (9)
CD3+CD4+CD8+ 3 (0) 10 (1)
Lymphocytes 
CD45+
1035 716 
NK cells 
(CD16+CD56+)
107 (10) 133 (18)
B-cells (CD19+) 164 (15) 381 (52)
 
 
Table 5  shows a table of peripheral blood cell subsets before and six months after HSCT. T-cells 
in peripheral blood remain suppressed 6 months after autologous HSCT. In contrast, T-suppressor 
lymphocytes, NK-cells and B-cells increase after the treatment. HSCT: haematopoietic stem cell 
transplantation. 
 
 
 
 
 
 
 
 
2.4 DISCUSSION 
 
This study underlines the importance of lymphocytes in SSc pathology and 
provides functional evidence for the association between lymphocyte infiltration 
and myofibroblast differentiation. For the first time, flow cytometry was applied for 
the analysis of dermal leukocytes in patients with SSc. The advantage of dermal 
flow cytometry is the possibility of multicolour flow analysis whereas in IHC co-
staining is technically difficult and usually limited to the detection of a few 
concomitant antigens. Furthermore, the amount of counted events is considerably 
higher in flow cytometry (38). Here we analysed between 767 and 12243 CD45+ 
leukocytes per staining, around 100.000 cells per skin biopsy. This is considerably 
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higher compared to IHC where analyses typically comprise counted cells of a few 
high power fields. 
One limitation of flow cytometry is the need to treat the tissue with collagenase. 
Surface antigens have to be collagenase resistant in order to be analyzed by this 
method. This has been tested beforehand in this study. Also, skin biopsies have to 
be processed immediately, which can be demanding logistically. 
It has been previously demonstrated that leukocyte infiltration occurs in SSc 
dermis in SSc (3-6). Lymphocytes, macrophages and mast cells have been 
identified as key infiltrating cells. Here we give evidence that in patients with diffuse 
SSc, lymphocytes are more prevalent whereas in skin of patients with limited SSc, 
macrophages are more prevalent. Lymphocyte infiltration correlates with skin 
thickening, suggesting an active role of lymphocytes in SSc fibrogenesis. This is in 
line with previous findings where T-cell transfer from bleomycine-treated mice led 
to fibrosis and autoantibody production in healthy mice (11). Blocking T-cell influx 
by CD3-antiserum abrogated lung fibrosis in bleomycine-treated mice and 
diseased T-cells stimulated fibroblast proliferation (40). It has therefore been 
postulated that (auto)activated T-cells in SSc stimulate fibroblasts and that T-cell 
control or regulation might be impaired, respectively. One explanation for the 
stimulation of fibroblasts could be the fact that lymphocytes (e.g. T-regulatory) cells 
in diffuse SSc secrete growth factors such as TGF-beta. Limited SSc has a more 
vasculopathic aspect compared to diffuse SSc were skin and lung fibrosis are 
more prevalent. The observation that macrophage infiltration is higher in the limited 
form of SSc is in line with a more ‘atherosclerotic’ pathogenesis, were 
macrophages infiltration in plaques and vessel wall, respectively are key 
pathogenic elements.  
In contrast, Langerhans cells in the epidermis are reduced in diffuse SSc patients 
(7). We had similar findings here in the dermis, albeit this did not reach 
significance, probably to the low sample number.  
We analysed TNF-alpha receptors as the role of these receptors in SSc is 
controversial and putative regulatory functions especially of TNF-R2 have been 
postulated in other settings. T-cells activated by CD3 ligation seem to inhibit 
collagen expression of fibroblasts in cell to cell contact by membrane associated 
TNF-alpha (32). On the other hand, TNF-receptors are necessary for bleomycine 
  80 
induced fibrosis and TNF-alpha blockade can inhibit scleroderma in bleomycine-
treated mice (41, 42). 
In line with previous findings, we found TNF-R2 upregulation mainly on 
lymphocytes (31). Conversely, TNF-R1 expression is ubiquitous, with most of the 
receptors being stored intracellularly, therefore not detectable by flow cytometry. In 
this study, TNF-R1 was expressed on a low level on lymphocytes, CD1a+ and 
CD14+ cells. TNF-R2 expression measured by mean intensity fluorescence was 
considerably higher and correlated with skin thickening, suggesting a profibrotic 
role of this receptor in SSc. The predominant upregulation of TNF-R2 has also 
been demonstrated in bleomycine treated mice (18) but also in renal allograft 
rejection (43). 
Functional studies of TNF-R were performed in CD3+ T-cells obtained from 
peripheral blood of SSc patients. Interestingly, the baseline expression of IL-6 
which is an inflammatory but also highly profibrotic cytokine was already higher in 
lymphocytes from SSc patients. This data was shown both in rtPCR and ELISA 
analyses.  
Upon selective TNF-R stimulation IL-6 expression was significantly higher in SSc 
patients, notably after TNF-R1 stimulation. The baseline of TGF-beta expression 
did not differ between SSc patients and healthy controls, but after selective TNF-
R2 stimulation, TGF-beta expression was higher SSc patients. IL-10, a potent anti-
inflammatory cytokine, was expressed after CD3/28 antigen stimulation. 
Interestingly CD3/28 activated SSc lymphocytes did not upregulate IL-10, neither 
IL-6 or TGF-beta. This might be due to an intrinsic dysfunction of SSc 
lymphocytes, a chronic TNF-alpha stimulation which renders lymphocytes tolerant 
towards antigen stimulation (44), or the influence of treatment such as 
cyclophosphamide. The lack of IL-10 upregulation might have implications e.g. in 
form of a disturbed resolution of inflammation.  
As a limitation of this study we performed functional studies in lymphocytes from 
peripheral blood and not isolated from skin. In the next experiments we 
demonstrated in a control cohort, that there is a correlation between lymphocytes 
and myofibroblasts in SSc dermis. This finding suggested that T-cell can trigger the 
differentiation of fibroblasts into myofibroblasts. To find this out we incubated 
healthy fibroblasts in conditioned medium from SSc lymphocytes which were 
previously treated with TNF-agonists. The results here showed different results. 
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Preliminary data indicate that conditioned medium from SSc T-cells inhibit the 
alpha SMA production of healthy fibroblasts. This is in line with previous findings 
where T-cell membranes extracted from dermal lymphocytes inhibited fibroblasts in 
producing collagen (32). This effect was attributed to TNF-alpha itself. Conditioned 
medium of TNF-alpha activated T-cells however triggered alpha SMA expression. 
One possible reason for the inhibition of alpha-SMA production might be the 
content of Interferon gamma which we have not measured in this study. We 
postulate that the higher amount of IL-6 after costimulation of lymphocytes by TNF-
alpha increases the alpha-SMA expression by fibroblasts. Previous studies already 
demonstrated that CD4+ cells control the differentiation of monocytes into collagen 
producing fibrocytes (45). This observation has been obtained from four 
consecutive patients in two independent experiments. Clearly, the effect of SSc 
lymphocytes with or without prior TNF-R activation on fibroblasts needs 
confirmation in a larger number of patients. The exact mechanism by which TNF-
activated lymphocytes stimulate fibroblasts remains elusive at this point. This is 
currently investigated by the group of Professor van Laar.  
In our last set of experiments we showed that this effect might be reversible. We 
analyzed the effect of HSCT on dermal infiltration of CD3+ lymphocytes and 
myofibroblasts. Both CD3+ T-cells and myofibroblasts infiltration decreased 
strikingly 6 months after the intervention. On detected lymphocytes, previously 
overexpressed TNF-R1 and R2 were not longer detected, suggesting a reset of 
lymphocytes from an activated into a normal state. The lower infiltration by 
leukocytes was also shown in peripheral blood were we observed a protracted 
decrease of CD4 T-helper cells but an increase of T-suppressor lymphocytes. 
In conclusion, we show that lymphocyte infiltration is of importance in SSc skin 
pathogenesis, presumably by interfering with the myofibroblast differentiation 
process. TNF-R2 is upregulated on dermal lymphcytes. TNF-R stimulation on 
lymphcytes has possibly profibrotic effects by IL-6 and TGF-beta production. TNF-
R overexpression in the skin is reversible after HSCT.   
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ABSTRACT 
 
OBJECTIVE: To investigate whether monocytes can act as a source of TIMP-1 in 
systemic sclerosis (SSc). 
METHODS: CD14+ Monocytes were isolated from blood of SSc patients and 
healthy controls using immunomagnetic beads. MMP-1 and TIMP-1 expression 
and secretion was measured by qRT-PCR and ELISA respectively. The functional 
effect of monocyte-derived TIMP-1 was studied in a MMP-1 activity assay. 
RESULTS: The expression of TIMP-1 in freshly isolated SSc monocytes was 
higher compared to healthy control monocytes (mean increase 3.1, SD 2.8, 
p=0.03). The addition of SSc serum to cultures of healthy monocytes increased 
expression of TIMP-1, but not of MMP-1, when compared to culutures with serum 
of healthy controls (mean increase 1.9, SD 1.2, p=0.01) and RA patients 1 (mean 
increase 1.7, SD 1.1, p=0.04). The secretion of TIMP-1 by healthy monocytes 
cultured in SSc sera also was significantly higher when compared to cultures with 
sera from healthy controls or RA patients (mean 16.8 (SD 9) vs. 9.1 (SD 2.4) and 
6.9 (SD 2.4) ng), p=0.01, p=0.04 respectively). Culture supernatants from 
monocytes cultured in SSc serum inhibited in vitro matrix degradation by 59% (SD 
2%) when compared to culture supernatants of monocytes cultured in healthy 
control serum (p=0.02). 
CONCLUSION: Circulating monocytes from SSc patients overexpress TIMP-1. 
TIMP-1 can be induced in healthy monocytes by soluble serum factors from SSc 
patients. Our findings suggest that circulating monocytes from SSc patients may 
contribute to matrix deposition via  perturbation of the TIMP/MMP balance in favor 
of TIMP-1. 
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3.1 INTRODUCTION 
 
Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease 
characterised by vasculopathy and fibrosis of the skin and inner organs. Low grade 
inflammation with tissue infiltration by mononuclear cells plays an important role in 
fibrogenesis [1]. Fibrosis in SSc is characterised by extensive accumulation of 
extracellular matrix, notably collagen, glycosaminoglycans and proteoglycans [2]. 
In addition to increased secretion of ECM components, impaired breakdown of 
ECM can also contribute to fibrosis [3]. ECM breakdown is mainly mediated by 
matrix metalloproteinases (MMP), a family of zinc dependent endopeptidases 
which are capable of degrading all matrix components [4]. Tissue inhibitors of 
metalloproteinase (TIMP) selectively inhibit these peptidases and can therefore 
inhibit ECM digestion [4, 5]. The TIMP family consists of four members; of those 
TIMP-1 is a key enzyme as it can inhibit most MMPs. [4]. Increased concentrations 
of TIMP-1 have been measured in serum of SSc patients [6, 7]. Fibroblasts 
isolated from the skin of SSc patients have been shown to overexpress TIMP-1 [8, 
9]. Several studies report an increase in the ratio of TIMP/MMP in SSc both in 
tissue and blood [7, 10-12]. In wound healing studies TIMP expressed by 
inflammatory cells such as monocytes or macrophages is important in tissue 
remodelling [13]. Recent studies have identified circulating monocytes as key 
inflammatory cells in SSc, showing profound dysregulation of gene expression [14, 
15]. 
We postulated that monocytes can act as a source of TIMP-1 in SSc and thereby 
contribute to the imbalance of TIMP-1/MMP which underlies fibrosis.  
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3.2 MATERIALS AND METHODS 
 
Study participants. 
23 patients with SSc, 16 healthy controls and 11 patients with active rheumatoid 
arthritis (DAS28 score >2.6) were included in the study. All SSc patients fulfilled 
the ACR criteria according to LeRoy . Informed consent was obtained from all 
patients and controls. The study was approved by the ethics committees from the 
participating centres. Table 1 shows disease characteristics and treatment status 
of the patients with SSc. 
 
 
Table 1. Twenty-three patients with SSc were included in the study. Data on gender, disease 
duration, limited or diffuse disease, auto-antibodies, rodnan skin score, lung involvement and 
cyclophosphamide treatment is provided. ACA: anti-centromere autoantibodies, Scl-70: anti-Scl70 
autoantibodies, ANA: anti-nuclear autoantibodies. 
 
 
Sample collection and cell purification.  
Whole blood was collected during standard outpatient procedures in either serum 
and/or EDTA containing tubes (BD Bioscience). The samples were processed 
 
 Disease characteristics SSc patients (n=23) 
 Female 80% 
 Disease duration. Years (Range) 8 (2-37) 
 Diffuse disease (%) 15 (65%) 
 Auto-antibodies (ACA / Scl-70 / ANA) 7 / 6 / 9 
 Rodnan skin score (Range) 11.6 (0-35) 
 Lung Fibrosis (%) 7 (39%) 
 Cyclophosphamide treated. 14 (61%) 
  91 
within 4 hours of collection. Serum tubes were centrifuged at 1800g for 10 minutes 
according to the manufacturer’s protocol. Total serum was harvested, aliquoted 
and frozen at -20°C. Peripheral blood mononuclear c ells (PBMC) were separated 
from whole blood by Ficoll-hypaque density gradient centrifugation (Axis-shield). 
CD14+ monocytes were isolated from total PBMC according to the manufacturer’s 
protocol with the CD14+ MACS beads isolation kit (Miltenyi- Biotec). In short, 
PBMC’s were suspended in PBS supplemented with 1% fetal-calf serum (Sigma-
Aldrich) and EDTA (2mM) plus CD14+ Miltenyi magnetic beads on ice for 20 
minutes. The total mixture was passed through a magnetic isolation column 
(Miltenyi Biotec). Purified CD14+ monocytes were removed from the column and 
tested for purity by flow cytometry. Flow cytometric analyses showed a >95% 
purity for CD14+CD3- cells. 
 
Cell culture. 
Cell culture experiments were carried out with CD14+ monocytes from healthy 
donors.  Up to 2*106 cells per well of a standard 24 well plate (Costar) were 
cultured for 4-24 hours in 250µl of Dulbecco’s Modified Eagle’s Medium 
(Invitrogen) supplemented with penicillin (100 units/ml), streptomycin (100 ug/ml), 
L-glutamin (2 mM) (all Sigma) and 10% serum from patients with SSc, patients 
with RA or healthy controls. Serum concentration was optimised through titration 
(Supplement 1). Cells were incubated at 37°C in atm osphere containing 5% CO2. 
The real time fluorescence based TIMP activity assay requires the use of serum-
free culture supernatant to exclude TIMP’s present in the serum. In order to obtain 
serum free culture supernatant, monocytes were cultured for 2 hours as described 
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above. After 2 hours, cells were washed twice with PBS and incubated in DMEM 
supplemented with penicillin, streptomycin and L-glutamin for additional 4 hours.   
 
TIMP-1 and MMP-1 expression analyses by quantitative Reverse 
Transcriptase-Polymerase Chain Reaction (qRT-PCR).  
RNA from adherent or freshly isolated monocytes was isolated using the RNA mini 
kit (Qiagen) according to the manufacturer’s protocol. 200-750 ng of RNA was 
treated with DNAse for 30 minutes at 37°C and rever se transcribed (RT) to cDNA 
with the use of random hexamers (Invitrogen) and the moloney murine leukemia 
virus-reverse transcriptase (MMLV-RT) enzyme (Invitrogen) according to the 
manufacturer’s protocol. 20 ng of cDNA, 0.6 µM forward and reverse primer, 
0.3µM probe and 0.2µl reference dye in 20µl total volume per well was used for 
TIMP-1 expression analyses by qPCR. MMP-1 expression was analysed using 
SYBERGREEN taqready mix (Sigma). Samples were analysed in triplicate and 
normalised to the 18S housekeeping gene using the AB7500 (Applied Biosystems) 
qPCR machine and program. Relative expression levels to the average healthy 
control were calculated using the following equation: (2^Delta Delta CT)-1. The 
primers and probe sequences for TIMP-1: forward primer 5'- 
GACGGCCTTCTGCAATTCC -3' reverse primer 5'-
GTATAAGGTGGTCTGGTTGACTTCTG -3' probe 5'-FAM- 
ACCTCGTCATCAGGGCCAAGTTCGT -TAMRA-3'. Primers and probe sequences 
for 18S: forward primer 5'-GAATGGCTCATTAAATCAGTTATGG-3' reverse primer 
5'-TATTAGCTCTAGAATTACCACAGTTATCC-3' probe 5'-FAM-
TCCTTTGGTCGCTCGCTCCTC- TAMRA-3'. Primer sequences for MMP-1: 
forward primer 5'-AGTGACTGGGAAACCAGATGCTGA-3' reverse primer 5'-
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GCTCTTGGCAAATCTGGCCTGTAA-3’. Primers, probes and 2x Taqready 
mastermix (with and without sybergreen) were obtained from Sigma-Aldrich. qPCR 
settings according to the Taqready mix manufacturer’s protocol. 
 
 
TIMP-1 Enzyme-Linked Immunosorbent Assay (ELISA).  
The TIMP-1 protein concentration in conditioned and unconditioned medium and 
sera was measured by ELISA as described before [16]. In short, plates (Costar) 
were coated with the primary antibody [16] overnight at 4°C in phosphate buffered 
saline (PBS, Sigma-Aldrich) and blocked with bovine serum albumin (BSA) 
(Sigma-Aldrich) in PBS (50 mg/ml) overnight at 4°C or for 2 hours at room 
temperature. The secondary biotinylated antibody was incubated for 2 hours at 
room temperature. Signal development was performed with HRP/Streptavidin for 
30 minutes at room temperature. OPD substrate and hydrogen peroxide in 
phosphate citrate buffer (all Sigma-Aldrich) were added. When colour development 
was sufficient, 50 µl of sulphate was added to stop the reaction. Fluorescence was 
measured with a plate reader (Tecan, Sunrise) at 490nm wave length. All samples 
were run in duplicate and diluted one in eight in order to fall within the detection 
limits of the assay (0-90 ng/ml). A titration of recombinant human TIMP-1 was used 
as calibration curve (Range 5-90 ng/ml) [16]. 
 
Real time fluorescence based TIMP activity assay.  
The functional effect of increased levels of TIMP-1 in monocytes was studied by a 
real time fluorescence based TIMP activity assay [17]. In this assay serum free 
culture supernatants derived from monocytes pre-incubated with 10% SSc patient 
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or healthy control serum is added to FS-6 (=fluorogenic substrate) and activated 
recombinant human MMP-1. The effect of supernatant on the breakdown rate of 
FS-6 by the activated MMP-1 is visualised using a Perkin Elmer LS50b plate 
reader. 
ProMMP-1 (generously donated by Dr. J. Milner) was activated by APMA (0.675 
mM) (Sigma) in 0.1M Tris, pH 7.5, 0.1 M NaCl, 10mM CaCl2, 0.05% Brij-35, 0.1% 
PEG 6000 for 4 hours at 37°C. Subsequently, MMP-1 w as incubated with serum 
free culture supernatants from monocytes pre incubated with either SSc patient or 
healthy control serum or plain DMEM for 15 minutes at 37°C. The mixture of 
culture supernatant and activated recombinant human MMP-1 was then added to 
separate wells containing FS-6 substrate (500 µM, Calbiochem). Fluorescence 
was measured by the Perkin Elmer LS50b exciting at 325nM and measured at 
400nM wave length. For each sample, the rate of breakdown was compared to the 
standard containing MMP-1 (6µg/ml), FS-6 (50µM) and unconditioned medium 
(plain DMEM, Sigma). Titration experiments using recombinant human TIMP-1 
were performed to study the MMP-1 concentration optimal for detecting differences 
in TIMP concentrations (Supplement 3).  
 
Statistical analysis. 
Differences in expression levels, protein concentration or substrate breakdown 
between SSc and control groups in all experiments were defined using a two tailed 
T-test. P-values <0.05 were considered significant. 
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3.3 RESULTS 
 
Serum TIMP-1 concentrations are higher in SSc patients versus healthy 
controls.  
TIMP-1 concentrations in sera from 18 SSc patients and 13 healthy controls were 
measured by ELISA (Figure 1A). The mean serum TIMP-1 concentration in SSc 
patients was 941 ng/ml (SD 325 ng/ml) compared to 637 ng/ml (SD 270 ng/ml) in 
healthy individuals (p=0.01), confirming previous work. Serum TIMP-1 
concentrations did not correlate with Rodnan skin score, disease onset, lung 
involvement, treatment status or autoantibody status. 
 
 
TIMP-1 but not MMP-1 is up-regulated in circulating monocytes from SSc 
patient. 
TIMP-1 and MMP-1 expression in CD14+ monocytes from 15 patients with SSc 
and 11 healthy controls was analysed (Figure 1B). Seven patients had diffuse SSc, 
6 of these patients were positive for Scl-70 auto-antibodies. The other patients had 
limited disease and were positive for either ACA or ANA. TIMP-1 expression in 
monocytes from patients with SSc, after normalisation to the 18S housekeeping 
gene, was significantly higher compared to monocytes from healthy controls 
(p=0.03). Mean expression of TIMP-1 in SSc monocytes was 3.1 fold (SD 2.8) 
higher compared to healthy control monocytes. The level of expression of TIMP-1 
did not correlate with autoantibody status of the SSc patients. MMP-1 levels were 
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below the detection limit of the assay in CD14+ monocytes from both healthy 
controls and SSc patients.  
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Figure 1. Overexpression of TIMP-1 in SSc CD14+ monocytes and the effect of SSc serum factors 
on TIMP-1 levels in CD14+ monocytes from healthy donors. A. TIMP-1 serum protein concentration 
by ELISA in SSc and healthy control serum (ng/ml). B. TIMP-1 expression levels in freshly isolated 
circulating CD14+ monocytes from patients with SSc and healthy controls by qPCR. C and D. 4 
hour expression (C) and secretion (D) of TIMP-1 by cultured CD14+ monocytes from healthy 
donors incubated in 10% SSc, RA or healthy control serum. E. MMP-1 expression by qPCR in 
CD14+monocytes cultured in 10% SSc or healthy control serum. Data show mean concentration, 
expression or secretion for the individual groups and SSc patient subgroups as defined by 
autoantibody positivity. B, C, D. Expression levels, normalised to the 18S housekeeping gene, are 
relative to the mean healthy control. Each dot represents the mean effect of one patient/control 
sample in multiple experiments (N=2-4). ACA: anti-centromere antibody, Scl-70: anti-Scl70 
antibodies, ANA: anti-nuclear antibodies.  *p<0.05, **p<0.01 
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Serum from patients with SSc up-regulates TIMP-1 in healthy monocytes.  
Monocytes from healthy donors were incubated in 10% serum from patients with 
SSc, healthy controls or serum from patients with rheumatoid arthritis (RA). Mean 
TIMP-1 expression levels of SSc serum cultured monocytes were 1.9 (SD 1.2) and 
1.7 (SD 1.1) fold higher compared to the mean of healthy control or RA patient 
serum cultured monocytes respectively (p=0.01, p=0.04). TIMP-1 expression was 
higher in monocytes cultured in sera containing Scl-70 auto-antibodies (mean 
expression levels were 2.6 vs 1.9 fold increased compared to mean healthy control 
sera (SD 1 – 4.25, p=ns)) (Figure 1C). Likewise, TIMP-1 protein secretion over 4 
hours as measured by ELISA was significantly higher after culture of monocytes 
from healthy donors in SSc sera as compared to healthy control or RA sera (16.8 
(SD 9.0) vs. 9.3 (SD 2.4) and 7.0 (SD 2.4) ng respectively) (p=0.0083, p=0.042 
respectively). The highest TIMP-1 levels were measured in cultures with anti-Scl-
70 positive sera (mean secretion of 24.4 ng (SD 13.4 ng) in 4 hours opposed to a 
mean of 16.8 ng (SD 9.0 ng) for all SSc sera) (Figure 1D). 
While MMP-1 levels of freshly isolated monocytes were undetectable, cultured 
monocytes did express low levels of MMP-1. MMP-1 expression levels were not 
significantly different (p=0.92) for monocytes cultured in SSc or healthy control 
serum (Figure 1E). 
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Figure 2. Functional TIMP-1 in supernatants from SSc serum-activated monocytes in MMP-1 
enzyme activity. Conditioned medium from SSc-serum activated monocytes significantly inhibits 
MMP-1 mediated substrate breakdown. Data of a representative experiment (n=3) are shown. (*= 
P<0.05 compared to the values of FS-6 +MMP-1) 
 
 
Supernatants from monocyte-cultures impairs substrate breakdown by MMP-
1. 
To investigate whether elevated levels of monocyte-expressed and secreted TIMP-
1 impairs substrate breakdown by MMP-1 we applied a functional matrix 
breakdown assay. FS-6 breakdown by MMP-1 was significantly (P=0.02) lower in 
the presence of supernatant from monocytes pre-incubated with SSc serum 
compared to healthy control serum or plain DMEM (Figure 2). A 59% (SD 2%) 
decrease in MMP-1 activity was demonstrated when culture supernatant from 
monocytes activated by SSc compared to those activated by healthy control serum 
was added to equal doses of active MMP-1. Data shown are from one 
representative experiment (n=3). In all 3 experiments sera of 3 different SSc 
patients and controls was tested. TIMP-1 concentrations in the supernatants of 
monocytes cultured in SSc serum was higher in all experiments as compared to 
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supernatants of monocytes cultured in serum from healthy controls. 
(supplementary data) 
 
 
3.4 DISCUSSION 
 
The importance of the innate immune system including circulating monocytes in 
the pathogenesis of systemic sclerosis (SSc) is increasingly recognized. 
Traditionally, monocytes are sees as prototypic pro-inflammatory cells, but recent 
evidence has shown that their functional capabilities extends beyond those of 
cytokine production alone. In the present study we wanted to explore the possibility 
that SSc monocytes can contribute to tissue fibrosis through preferential up-
regulation of TIMP-1 as opposed to MMPs. This was based on the observation of 
increased serum TIMP-1 concentrations in SSc patients  [6, 7] and the fact that 
some macrophage subsets have a repair phenotype.  
Our findings indeed strongly suggest that monocytes can play an important role in 
fibrogenesis. We found that TIMP-1 but not MMP-1 gene expression is higher in 
freshly isolated SSc monocytes compared to healthy control monocytes. 
Interestingly, serum from SSc patients induced expression and secretion of TIMP-1 
but not MMP-1 in healthy monocytes, thus generating a profibrotic state [7, 10-12]. 
This shift in balance towards TIMP-1was functionally relevant as shown by the 
results from the matrix degradation assay. These results could translate into 
increased matrix deposition in skin, blood vessels and internal organs. Our findings 
suggest that factor(s) in serum from SSc patients are responsible for the imbalance 
between TIMP-1/MMP as observed in SSc monocytes.  
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The observation of profibrotic properties of monocytes are in line with recent 
findings on the identification of two different subsets of monocytes/macrophages: a 
pro-inflammatory (M1) and a profibrotic (M2) subset. The M2 subset, characterized 
by expression of CD163 and CD202 and an important source of the pro-fibrotic 
cytokines such as TGF-β, has been identified in SSc skin and serum [18]. Another 
study found that in SSc patients with interstitial lung disease, CD14+ monocytes, in 
response to LPS, are skewed towards the pro-fibrotic phenotype and overexpress 
the M2 marker, CD163 and IL-10 and CCL-18, both known to stimulate collagen 
secretion by fibroblasts [19].  
 
Taken together, our data indicate that SSc monocytes are skewed towards a pro-
fibrotic state. Monocytes could thus play a role in the accumulation of collagen by 
inhibiting breakdown as a result of perturbation of the balance of TIMP/MMP in 
favor of TIMP-1. The exact mechanism by which monocytes become profibrotic 
remains to be investigated. The cytokine and or auto-antibody milieu is likely to 
play a major role in this regard. 
 
 
  101 
3.5 REFERENCES. 
 
1. Sapadin AN, Esser AC, Fleischmajer R. Immunopathogenesis of scleroderma--
evolving concepts. J Mt Sinai Hosp NY 2001; 68:233-42. 
2. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. 
J Clin Invest 2007;117:557-67. 
3. Yoshiji H, Kuriyama S, Miyamoto Y, Thorgeirsson UP, Gomez DE, Kawata M, et al. 
Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a 
transgenic mouse model. Hepatology 2000;32:1248-54. 
4. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of 
metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92:827-
39. 
5. Woessner JF, Jr. Matrix metalloproteinases and their inhibitors in connective tissue 
remodeling (review). Faseb J 1991; 5:2145-54. 
6. Young-Min SA, Beeton C, Laughton R, Plumpton T, Bartram S, Murphy G, Black 
C, Cawston TE. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic 
sclerosis, primary Raynaud’s phenomenon, and in normal controls. Ann Rheum 
Dis 2001;60:846-51. 
7. Montagnana M, Volpe A, Lippi G, Caramaschi P, Salvagno GL, Biasi D, et al. 
Relationship between matrix metalloproteinases/tissue inhibitors of matrix 
metalloproteinases systems and autoantibody patterns in systemic sclerosis. Clin 
Biochem 2007;40:837-42. 
8. Kuroda K, Shinkai H. Gene expression of types I and III collagen, decorin, matrix 
metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts 
from patients with systemic sclerosis. Arch Dermatol Res 1997;289:567-72. 
  102 
9. Bou-Gharios G, Osman J, Black C, Olsen I. Excess matrix accumulation in 
scleroderma is caused partly by differential regulation of stromelysin and TIMP-1 
synthesis. Clin Chim Acta 1994;231:69-78. 
10. Iredale JP, Benyon RC, Arthur MJ, Ferris WF, Alcolado R, Winwood PJ, et al. 
Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced 
relative to interstitial collagenase messenger RNA in experimental liver injury and 
fibrosis. Hepatology 1996;24:176-84. 
11. Kikuchi K, Kubo M, Hoashi T, Tamaki K. Decreased MMP-9 activity in the serum of 
patients with diffuse cutaneous systemic sclerosis. Clin Exp Dermatol 2002; 
27:301-5. 
12. Kikuchi K, Kubo M, Sato S, Fujimoto M, Tamaki K. Serum tissue inhibitor of 
metalloproteinases in patients with systemic sclerosis. J Am Acad Dermatol 1995; 
33:973-8. 
13. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999;341:738-46. 
14. Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA, Chen G, Breen P, 
Buckner JH, Molitor JA et al. Combined analysis of monocyte and lymphocyte 
messenger RNA expression with serum protein profiles in patients with 
scleroderma. Arthritis Rheum 2008;58:1465-74. 
15. York MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, Lafyatis R. A 
macrophage marker, Siglec-1, is increased on circulating monocytes in patients 
with systemic sclerosis and induced by type I interferons and toll-like receptor 
agonists. Arthritis Rheum 2007;56:1010-20. 
16. Clark IM, Powell LK, Wright JK, Cawston TE. Polyclonal and monoclonal 
antibodies against human tissue inhibitor of metalloproteinases (TIMP) and the 
  103 
design of an enzyme-linked immunosorbent assay to measure TIMP. Matrix  
1991;11:76-85. 
17. Neumann U, Kubota H, Frei K, Ganu V, Leppert D. Characterization of Mca-Lys-
Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, a fluorogenic substrate with increased 
specificity constants for collagenases and tumor necrosis factor converting 
enzyme. Anal Biochem 2004;328:166-173. 
18. Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, et 
al. Characterization of monocyte/macrophage subsets in the skin and peripheral 
blood derived from patients with systemic sclerosis. Arthritis Res Ther 2010; 
12:R128. 
19. Mathai SK, Gulati M, Peng X, Russell TR, Shaw AC, Rubinowitz AN, et al. 
Circulating monocytes from systemic sclerosis patients with interstitial lung disease 
show an enhanced profibrotic phenotype. Lab Invest 2010;90:812-23. 
 
 
 
 
 
 
  104 
CHAPTER 4 
 
 
Mast Cells are a Source of Transforming Growth Factor (TGF) 
beta in Systemic Sclerosis 
 
 
 
Thomas Hügle1,2, Vanessa Hogan1, Kathryn White3, Jacob M. van Laar1 
 
 
1 Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle 
University, United Kingdom  
2 Department of Rheumatology, Felix-Platter-Spital, University Hospital of Basel, 
Basel, Switzerland 
3
 EM research services, Newcastle University, United Kingdom  
 
 
Published in Arthritis and Rheumatism 2011;63(3):795-9. 
 
  105 
ABSTRACT 
 
Objective. To describe the cellular source of transforming growth factor (TGF) 
beta in the dermis of patients with systemic sclerosis (SSc). 
Methods. We performed gold labelled immuno electron microscopy (EM) on skin 
biopsies of seven SSc patients and three healthy controls. For TGF-beta 
quantification, gold particles per square micron were calculated. Mast cell origin 
was confirmed and quantified by toluidine blue staining and light microscopy. De-
granulation was assessed on toluidine blue sections and EM images. 
Results. In all patients, active TGF-beta was uniquely observed in mast cell 
vesicles, some of which were released into the extracellular space. Patients with 
progressive SSc and a more recent onset of non-Raynaud’s phenomenon 
symptoms had higher numbers of mast cells and gold particles per mast cell. Mast 
cells in healthy controls also contained active TGF-beta but in contrast to SSc 
samples showed a resting character with no or low-level de-granulation and 
uniformly dense osmiophilic vesicles. 
Conclusion. De-granulation of skin mast cells can be an important mechanism of 
TGF-beta secretion in SSc.  
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4.1 INTRODUCTION 
 
Systemic sclerosis (SSc) is a heterogeneous connective tissue disease presenting 
with low grade inflammation and vasculopathy, which together lead to fibrosis of 
skin and inner organs. Transforming growth factor (TGF) beta is a key player in 
fibrosis and has shown to be of paramount importance in SSc (1). It has been 
convincingly demonstrated that TGF-beta contributes to fibrosis via the activation 
of increased levels of TGF-beta receptors on fibroblasts (2), leading to activation of 
the Smad pathway and stimulation of fibroblasts to express collagen or 
differentiate into myofibroblasts (3). There are reports of several cell lines 
expressing or storing TGF-beta in SSc. Notably fibroblasts, endothelial cells, 
thrombocytes, monocytes and macrophages are considered to synthesise TGF-
beta (4). In SSc dermis, the expression of TGF-beta is most prominent around 
vessels. It is associated with infiltrating mononuclear cells and it co-localizes with 
type-1 collagen expression (5-7). However so far it has not been demonstrated 
which of these cells are mainly responsible for TGF-beta expression in SSc. 
Mast cells are vesicle-containing secretory cells resident in the connective tissue, 
notably in the skin, respiratory system and gastrointestinal tract. Activation such as 
in hypersensitivity or anaphylaxis leads to the release of various tissue mediators, 
including vasoactive amines, proteinases and also TGF-beta (8, 9). Their proximity 
to fibroblasts makes mast cell products available to fibroblasts and stimulates them 
to produce collagen (4, 9). 
In SSc, the number of mast cells is increased both in involved and uninvolved skin, 
but the number of de-granulated mast cells is increased only in involved skin (10).  
In this report we demonstrate by electron microscopy (EM) immunogold-labelling 
that mast cells are a major source of TGF-beta in SSc.  
 
 
4.2 PATIENTS AND METHODS 
 
4 mm dermal punch skin biopsies of involved skin from the forearm were obtained 
from 7 SSc patients (4 with diffuse cutaneous SSc and 3 patients with limited 
cutaneous SSc) (Table 1), all of which fulfilled the ACR criteria for SSc (11). The 
disease course was categorized as improving, stable or progressive depending on 
  107 
the change of skin thickening and/or organ function in the year preceding skin 
sampling. Control skin samples were obtained from the forearm in one, and from 
breast-reduction surgery in two healthy individuals. Ethical approval and written 
consent was obtained before the intervention. Skin biopsies were fixed in 1% 
paraformaldehyde and embedded in LR white resin. For immuno-staining we used 
a monoclonal mouse antiserum reactive against active human TGF-beta1,2 
isoforms (R&D systems) and a gold labelled secondary antibody. Staining with 
gold-labelled secondary antibody without primary antibody served as a negative 
control in each experiment (Fig. 1). Sections were examined on a Philips CM100 
transmission EM.  
For quantification we calculated the mean number of gold particles per square 
micron in all detected mast cells per sample. Toluidine blue (Sigma) stained 
sections and light microscopy were used to confirm mast cells. To determine the 
prevalence of mast cells we counted toluidine blue positive cells per x100 
magnification field. De-granulation was assessed both by toluidine blue staining 
and EM and scored blinded as absent (-), mild (+), moderate (++) or extensive 
(+++).  
 
 
Figure 1. Negative control. A. Immuno electron microscopy with anti-TGF-beta antiserum and 
secondary, gold-labelled antibody. B. The same experiment without primary antibody. 
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4.3 RESULTS 
  
Active TGF-beta was uniquely detected in mast cells. Figure 2A shows a mast cell 
in proximity of fibroblasts and a proliferating vessel. On higher magnification 
(Figure 2B), TGF-beta is seen abundantly in the vesicles of this mast cell. Some 
TGF-beta containing vesicles are released into the extracellular space (Figure 2C). 
To confirm that these were mast cells serial sections were stained with toluidine 
blue and examined with light microscopy or processed for immuno-EM, 
respectively (Fig 2 D,E). No other cells, notably lymphocytes, fibroblasts or 
macrophages were positive for TGF-beta in the patients. 
 
 
 
Figure 2. Immuno electron microscopy and –histology of the dermis of SSc patients. A. A mast cell 
with typical morphology is seen in close proximity to a fibroblast (arrow) and a proliferated vessel 
(arrowhead). B. On a higher magnification, abundant gold particles are seen in the mast cell 
vesicles. C. TGF-beta is released by mast cell de-granulation in the extracellular space. D and E. 
The nature of mast cells are confirmed in serial sections stained with immunohistochemistry and 
toluidine blue.  
 
 
Mast cells were more prevalent (≥ 4 per visual field) in patients with progressive 
disease and a more recent SSc onset (≤ 3 years) (Table 1). The two patients with 
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the highest modified Rodnan Skin Score also had the highest numbers of mast 
cells with up to 6 toluidine blue stained cells in a single field (Figure 4). Patients 
with stable or improving disease had very few mast cells (≤ 1 per visual field).  
The number of gold-labelled TGF-beta molecules per square micron in mast cells 
was also higher in patients with a progressive disease course compared to those 
with a stable course. One patient with a relatively high skin score who had 
successfully been treated with hematopoietic stem cell transplantation prior to skin 
sampling only had low mast cell numbers and gold particles per mast cell. We 
found mast cell de-granulation in five out of seven patients. One patient had diffuse 
scattering of TGF-beta containing vesicles throughout the dermis, three patients 
had moderate de-granulation whereas mild or no de-granulation was found in other 
three patients.   
Mast cells in all three healthy samples also contained TGF-beta confined to 
vesicles with a mean number of 19 gold-labelled TGF-beta molecules per cell.  
However, two healthy samples had a dermal mast cell number per field of 2 with 
mild  de-granulation and one healthy individual had a maximum of 5 mast cells per 
field without de-granulation. With standard EM we observed heterogeneity in mast 
cell vesicle density in the SSc samples compared to a more homogeneous pattern 
of osmiophilic structures in healthy controls (Figure 3). Some SSc mast cell 
vesicles were fused in the form of a ‘tunnel’. These findings reflect an active state 
of mast cells in SSc skin.  
 
 
Figure 3. Standard electron microscopy illustrating mast cell vesicle morphology. A. Mast cells of 
healthy individuals show uniformly dense osmiophilic vesicles whereas vesicle density in SSc 
samples was more heterogeneic (asterisks) indicating a higher mast cell activity. B. High 
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magnification of mast cell vesicles in SSc patients showed a fusion of vesicle membranes with each 
other and the cell membrane, respectively (arrows). 
 
 
 
 
Figure 4. Dermal mast cell infiltration in SSc patients 1-7 and a healthy control shown by positive 
Toluidine blue staining (arrows). Patients numbers refer to table 1. Patient 1-3 who suffered from 
progressive disease course had higher numbers of mast cells in the dermis (magnification x100). 
HC: healthy control. 
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4.4 DISCUSSION 
 
In this study we identified de-granulating mast cells as a major source of active 
TGF-beta in skin of SSc patients. Both the number of mast cells and detectable 
TGF-beta in mast cells are higher in patients with a more recent onset and 
progressive disease, respectively. This suggests that the release of TGF-beta by 
mast cells and trafficking in vesicles could be of importance in the pathogenesis of 
SSc, e.g. through inflammatory cell attraction or fibroblast stimulation. Functional 
analyses, however, will be necessary to confirm the pro-fibrotic role of mast cells in 
SSc. Furthermore we cannot exclude that immuno-EM is not sensitive enough to 
detect lower levels of TGF-beta when expressed in other cells. It is possible that 
TGF-beta anchored in the latent TGF-beta complex could not be detected in these 
experiments because of a masked epitope. 
Nonetheless, our analysis demonstrates that de-granulating mast cells are a 
source of TGF-beta in SSc and thus might actively contribute to fibrosis by 
activation of fibroblasts. This is in line with findings in other fibrotic diseases where 
mast cells promote collagen deposition and represent a potential therapeutic target 
(12, 13). As expected, physiological TGF-beta storage in vesicles of resting mast 
cells from healthy individuals was found. In contrast, ongoing de-granulation, a 
higher number of mast cells and mast cell activity reflected by the heterogenic 
vesicle coloration and fusion of vesicles indicate a higher TGF-beta turnover by 
mast cells in SSc patients. 
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Table 1. Patient characteristics, mast cell numbers and TGF-beta labelling per mast cell. Mast cells were quantified as toluidine blue positive cells. The 
maximal number of infiltrating cells per x100 magnification field is indicated. Gold particles per square micron were counted in all identified mast cells per 
biopsy. De-granulation was assessed by toluidine blue staining and electron microscopy and scored as absent (-), mild (+), moderate (++) or extensive (+++). 
MRSS: modified Rodnan Skin Score, RA: rheumatoid arthritis, HSCT: hematopoietic stem cell transplantation. Cyc: Cyclophosphamide, MTX: Methotrexate. 
 
Patient Gender Age 
(years) 
Disease duration 
(years since first 
non-Raynaud) 
Subtype mRRS Immunosup
pressive 
treatment 
Disease 
course 
Max. number 
of mast 
cells/field  
Gold particles/sq 
micron 
Mast cell de-
granulation 
1 Male 76 3 Diffuse 35 Cyc Progressive 6 11.7 ++ 
2 Female 58 2 Diffuse 30 MTX Progressive 6 9.1 +++ 
3 Female 55 3 Limited 9 - Progressive 4 9.8 ++ 
4 Female 46 3 Limited 8 - Stable 3 7.8 ++ 
5 Male 57 10 Diffuse 20 Cyc Stable  2 6.0 - 
6 Female 63 12 Limited, 
RA 
overlap 
9 - Stable  4 6.9 + 
7 Female 57 4 Diffuse 28 Autologous 
HSCT 
Improving 1 1.5 - 
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ABSTRACT 
Objectives: To describe and analyse the manifestation of sclerosing skin disorders in 
patients with multiple sclerosis (MS). Case reports: We describe three patients with 
relapsing remitting MS who developed skin sclerosis while receiving interferon (IFN)-
beta treatment and review nine further cases of systemic sclerosis (SSc) in MS from 
the 
literature. Of all 12 patients reported, eight had limited cutaneous SSc, three had 
diffuse cutaneous SSc and one patient had an antisynthetase syndrome. Localised 
scleroderma such as morphoea  was not described. The mean age at diagnosis was 
25.2 years for MS (range 12 to 51) and 38.3 years for SSc (range 16 to 66). Eleven 
patients developed SSc after the onset of MS and manifested with skin sclerosis after 
a mean of 14.9 years (range 1 to 45). In five patients IFN-beta was commenced 
before the development of skin sclerosis (mean 4.6 years, range 1 to 8 years). There 
was no relationship between the onset of skin sclerosis and MS activity. With the 
exception of one individual, all patients had antinuclear antibodies. Conclusions: 
Sclerosing skin disorders may develop in the course of MS. The relatively early age 
of SSc onset in patients with MS suggests a genetic predisposition and/ or an IFN-
associated trigger.  
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5.1 INTRODUCTION 
 
Multiple sclerosis (MS) is a demyelinating disease mediated by autoreactive T cells. 
Although a report suggested an increased prevalence of Sjögren’s syndrome, an 
association between MS and connective tissue diseases (CTD) has not been 
confirmed in a large cohort.1 Interferon (IFN)-beta is frequently used in the treatment 
of relapsing-remitting MS. IFN-beta may stimulate autoantibody production, induce 
autoimmune disorders in the thyroid and other organs, and precipitate Raynaud’s 
phenomenon.2 A parallel occurrence of MS and systemic sclerosis (SSc) has only 
been described in a few individuals. Here, we describe three patients who were 
referred to our tertiary care hospital suffering from MS and having developed a 
sclerosing skin disorder while receiving IFN-beta treatment. We review the evidence 
for a link between both autoimmune conditions, and the triggering of skin sclerosis by 
IFN.   
 
5.2 CASE REPORTS 
Patient 1 
A 54-year-old female patient had developed relapsing-remitting MS at the age of 12 
years. Since 47 years of age, she had received corticosteroids and IFN-b, under 
which her MS remained stable. At the age of 53 years under continued IFN- 
treatment she noticed Raynaud’s phenomenon with oedema, sclerodactyli and 
hyperpigmentation of the nail beds. Digital ulcers, telangiectasias or synovitis were 
not present. She had dilated and distorted nail fold capillaries. There were no 
symptoms of gastro-oesophageal reflux. Echocardiography, lung function tests and a 
high resolution computed tomography of the chest were normal, but anticentromere 
autoantibodies were positive (titre 1:5210). Treatment with IFN-beta was not 
discontinued. The skin status remained stable and follow-up echocardiography and 
lung function test were normal after 2 years.  
 
Patient 2 
A 66-year-old woman had developed relapsing remitting MS at 21 years of age. IFN-
beta treatment was commenced at 58 years of age and had led to a complete 
stabilisation of the disease. Eight years after the initiation of IFN-b, she noted 
Raynaud’s phenomenon, arthralgia, myalgia and sclerodactyli. She had not 
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developed digital ulcers, telangiectasias, dysphagia or sicca symptoms. A nail-fold 
capillaroscopy and a computerised tomography of the chest were normal. Her 
antinuclear antibody (ANA) titre was 1:80, anti-Jo-1 and anti-SSA autoantibodies 
were positive. After 5 months without cessation of IFN, her skin status remained 
stable. At this time, a gastric carcinoma was diagnosed.  
 
Patient 3 
A 59-year-old man was known for relapsingremitting MS since the age of 51 years. 
Since then he had received IFN-beta although this treatment could not fully prevent 
recurrent episodes of MS progression. Since the age of 58, Raynaud’s phenomenon, 
sclerodactily and digital ulcers were observed. He had no dysphagia. 
Echocardiography, high resolution computed tomography and lung function testing 
did not reveal evidence of cardiac or pulmonary involvement. His nail-fold 
capillaroscopy was normal but anticentromere autoantibodies were positive (titre 
1:1280).  
 
We have described three patients with relapsing remitting MS who developed a 
sclerosing skin disorder 7–8 years after the initiation of IFN-beta treatment. Two 
patients were diagnosed with limited cutaneous scleroderma (lcSSc) and the third 
patient had skin sclerosis in association with antisynthetase autoantibodies  
In the literature, we found nine further cases of MS in association with SSc (table 1). 
Six cases had lcSSc, and three had diffuse cutaneous SSc (dcSSc). Localised 
scleroderma such as morphoea or ‘‘en coup de sabre’’ has not been described. Eight 
individuals had MS prior to the onset of SSc; in only one individual MS developed 
after the onset of SSc. One patient, who had had Raynaud’s phenomenon for 11 
years, developed SSc 1 year after receiving IFN for MS. All but one patient had 
elevated ANA titres. The onset of skin sclerosis was dissociated from MS activity in 
most of the patients. In all 12 patients, the mean age of MS diagnosis was 25.2 years 
(range 12–51). The mean age at the onset of skin sclerosis was 38.3 years (range 
16–66). Skin sclerosis was therefore preceded by the MS by a mean of 14.9 years 
(range 
1–45). Five of the 11 patients who developed skin sclerosis after the onset of MS had 
received IFN-b. After the initiation of IFN treatment, skin sclerosis developed after a 
mean of 4.6 years (range 1–8). Interestingly, lung fibrosis did not progress and 
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Raynaud’s phenomenon improved after cessation of IFN treatment in one MS 
patient.3 The literature also reports three patients who developed skin sclerosis while 
receiving IFN-a, another type 1 IFN (table 1). Patients had either simultaneous 
chronic hepatitis C virus infection or myeloproliferative disease and had developed 
skin sclerosis after a mean of 1.2 years (range 0.5–1.7) of IFN-alpha treatment. All 
patients were female and all had high-titre ANAs. Two patients had SSc, one patient 
had a PM-Scl positive collagenosis.  
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 Age at onset of first 
disease (years) 
Gender Time of IFN treatment prior to 
second disease (years) 
Age at onset of 
second disease 
(years) 
Clinical features of SSc Nail-fold 
capillaroscopy 
 ANA titre  ANA 
specificity 
SSc in the course of MS 
        
Patient 1 12 Female  6 (IFN-beta) 53 sclerodactily, RP Positive 1:5210 Centromere 
Patient 2 21 Female  8 (IFN-beta) 66 RP, limited scleroderma, puffy hands Negative 1:80 SSA, Jo1 
Patient 3 51 Male 7 (IFN-beta) 58 sclerodactily, digital ulcers   1:1280 Centromere 
Pelidou et al 2007 26 Female  1 (IFN-beta) 34 RP, limited scleroderma, digital ulcers, lung 
fibrosis, oesophageal dysmotility, 
stabilisation after IFN cessation 
ND 1:5120  
         
Spadaro et al 1999 20 Female 1 (IFN-beta) 27 diffuse scleroderma, digital ulcers Positive Positive Scl70, 
U1RNP 
         
Igarashi et al 1989 27 Female No IFN 39 RP, diffuse scleroderma, lung fibrosis, 
oesophageal dysmotility 
ND Positive Scl70 
         
Gorodkin et al 2004 37 Female No IFN 47 RP, limited scleroderma, digital ulcers, 
calcinosis, oesophageal dysmotility 
 Positive Negative 
Gorodkin et al 2004 28 Female No IFN ND RP, sclerodactily, oesophageal dysmotility   ND Centromere 
Jawad et al 1997 22 Female No IFN 43 RP, limited scleroderma, oesophageal 
dysmotility 
ND 1:320  
Trostle et al 1986 15 Female No IFN 16 RP, limited scleroderma digital pitting 
scars, telangiectasias, calcinosis, lung 
fibrosis 
ND 1:320  
Trostle et al 1986 16 Female No IFN 19 RP, diffuse scleroderma ND 1:40 –    
MS in the course of SSc 
        
Chroni et al 2002 20 Female No IFN 22 Limited scleroderma (face and hands)  ND 1:640 Scl70 
SSc in the course of IFN 
treatment for chronic HCV 
infection 
        
Tahara et al 2007 50 Female 1.5 (IFN-alpha) 68 limited scleroderma (fingers, forearms)  Negative 1:1280  
Solans et al 2004 47 Female 0.5 (IFN-alpha) 47  sclerodactily, telangiectasias, calcinosis, 
lung fibrosis, improvement after IFN 
discontinuation 
Positive 1:1280 PM-Scl 
SSC in the course of IFN treatment for chronic 
myelogenous leukaemia 
       
         
Beretta et al 2004 52 Female 1.7 (IFN-alpha) 54 Limited scleroderma (fingers, wrists), lung 
fibrosis, alveolitis, PAH, oesophageal 
dysmotility 
Positive Positive Scl70 
 
Table 1. The three patients in our case series and all nine found in literature are listed. Patients who developed skin sclerosis after receiving IFN-alpha treatment 
for HCV infection and myeloproliferative disease are also listed. ANA, antinuclear antibody; HCV, hepatitis C virus; IFN, interferon; MS, multiple sclerosis; ND, not 
done/not described; PAH, pulmonary arterial hypertension; RP, Raynaud’s phenomenon; SSc, systemic sclerosis. 
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5.3 DISCUSSION 
The cluster of the three cases described here and a further nine patients 
found in the literature prompted us to investigate a possible relation between 
MS and SSc. The presence of these two autoimmune diseases in the same 
individual raises the question whether or not this association reflects pure 
coincidence, an underlying predisposition to develop both autoimmune 
diseases, or the stimulation of skin sclerosis by IFN. A gadolinium triggered 
dermopathy could be ruled out based on a 
normal renal function and the presence of Raynaud’s phenomenon in these 
patients. 
Although there is no clear proof of other autoimmune complications in patients 
with MS themselves, an increased risk for autoimmune disease was 
demonstrated in first-degree relatives of patients with MS.4 Conversely, 
approximately one-third of SSc 
patients were found to have at least one additional autoimmune disease.5 The 
observation that the onset of skin sclerosis in patients with MS was 9 years 
before the mean age reported in the large European Scleroderma Trial and 
Research cohort (EUSTAR)6 may also be interpreted as an underlying genetic 
predisposition. To this end, it is noteworthy that an otherwise rare allele in the 
CD45 gene has been found in relatively high frequency in both, patients with 
MS and SSc.7 This CD45 allele may enhance T cell receptor signalling and 
may thus represent a genetic risk factor for both autoimmune diseases.7 
Elevated ANA titres are found in up to 45% of patients with MS. Although ANA 
titres usually remain low in patients with MS, they are known to be increased 
by IFN-beta exposure.8 Large observational studies have described the 
induction of new autoantibodies in up to 61%, and autoimmune complications 
in 4–19% of IFN-treated individuals.2 The dynamics of de novo autoantibody 
induction in patients with MS by IFN appears to be delayed, however, as ANA 
were usually not observed during the first 6 months of IFN treatment. In most 
of the patients  
with MS summarised here, it is unknown if ANA were present before IFN was 
commenced. It is, however, well known that autoimmune thyroiditis, a frequent 
complication of IFN treatment, develops preferentially in subjects harbouring 
preexisting antithyroid autoantibodies.2 Among the CTDs, de novo 
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manifestations of systemic lupus erythematosus have been observed under 
IFN-a and IFN-beta treatment,9 the duration of IFN exposure ranging from 1 
month to 7 years. Conversely, systemic lupus erythematosus was observed to 
resolve in some cases in which IFN-beta was discontinued.10 A placebo-
controlled randomised study has examined IFN-a as a possible treatment for 
SSc.11 In this trial, IFN actually worsened some SSc manifestations and even 
increased SSc mortality,11 supporting the possibility that IFN contributes to 
skin sclerosis. In MS, autoreactive T cells are thought to play an important 
pathogenic role. In SSc, activated fibroblasts and endothelial cells have 
mainly been implicated in the vascular damage and fibrosis, 
but an antigen-driven T helper 2 (Th2) cell activation with consequent 
enhancement of interleukin 4 expression was also identified in the aetiology of 
active SSc.12 A similar Th2 cytokine pattern also characterises patients with 
MS after the initiation of 
IFN-beta treatment.13 Because Th2 cytokines were shown to activate 
fibroblasts, it is conceivable that the IFN-mediated Th2 shift contributes to the 
development of skin sclerosis.14 The possible role of IFN as a trigger of skin 
sclerosis is further supported by cases in which fibrotic complications resolved 
or stabilised after IFN cessation.15 On the other hand, only five patients with 
MS had received IFN before the appearance of SSc. We thus conclude that 
IFN may be a possible, albeit not necessary cofactor for the development of 
SSc in patients with MS. The decision as to whether IFN treatment should be 
discontinued in such cases can only be interdisciplinary and should be 
individualised on basis of the activity of both diseases, 
the available therapeutic options, and the patient’s personal priorities.  
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ABSTRACT 
 
Objective. The clinical course of systemic sclerosis (SSc) depends on 
subtype, organ involvement and age. Few data are reported on patients 
suffering from late onset SSc.  
Methods. We analyzed data from 8,554 patients prospectively followed in the 
EULAR Scleroderma Trials and Research (EUSTAR) group database. Late 
onset SSc was defined as onset of non-Raynaud’s disease features at or 
beyond 75 years of age. Disease characteristics, clinical features, disease 
course and mortality were evaluated. 
Results. A total of 123 patients with SSc onset at or beyond 75 years of age 
were identified. Compared to patients <75 years they had more frequently 
limited than diffuse SSc and a higher prevalence of anti-centromere 
autoantibodies. Fewer old patients had digital ulcers. The modified Rodnan´s 
skin score, the prevalence of lung fibrosis and renal crisis did not differ 
significantly between groups. Pulmonary hypertension (PH) measured by 
echocardiography was more prevalent in the late onset group, as well as 
arterial hypertension and diastolic dysfunction. Late onset SSc remained a 
positive predictor for PH in multivariate analyses. No significant difference of 
the two groups in skin score or diffusion capacity was observed during follow 
up. Mortality due to SSc was higher in the late onset group, but the survival 
time from diagnosis was longer compared to the younger patients. 
Conclusion. Late onset SSc shows a distinct clinical presentation and 
outcome. Patients with late onset SSc suffer more frequently from the limited 
subtype and PH but fewer patients have digital ulcers. PH may in part be 
determined by underlying cardiovascular disease. 
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6.1 INTRODUCTION 
 
Systemic Sclerosis (SSc) is a heterogeneous connective tissue disease. 
Whereas vasculopathy in form of digital ulcers or pulmonary hypertension 
(PH) is the leading clinical feature in the limited form, diffuse SSc is 
associated with progressive fibrosis of skin and inner organs. The clinical 
presentation also depends on age. Patients with juvenile onset SSc have less 
skin involvement and lower mortality but suffer more frequently from overlap 
syndromes, notably with skeletal muscle involvement (116). In contrast, 
patients with onset of Raynaud’s phenomenon above the mean age suffer 
more frequently from digital ulcers, lung fibrosis, PH and diastolic heart failure 
(117). The mean age at onset of first non-Raynaud’s phenomenon in the 
EULAR Scleroderma Trials and Research (EUSTAR) database was reported 
44.8 years for diffuse SSc and 47.9 years for limited SSc (117). In a North 
American SSc cohort study, white patients had an older age at diagnosis 
(55.5 years) compared to black patients (43.8 years) (118). Among white 
patients, the peak incidence was between 65 and 74 years in women and >75 
years in white men (118). The incidence of SSc >75 years is around 20 cases 
per million per year which is 2-4% of all SSc cases (118). 
Data indicate that a late age at onset of SSc is associated with more 
aggressive disease (119). In fact, the risk of death increases by 5% for each 
1-year increase in age at diagnosis (118). The number of patients >75 years 
at diagnosis in previous studies however is low and naturally occurring co-
morbidity in the elderly certainly influences survival analysis. Only small SSc 
cohorts or case series have focused on late onset SSc. Whereas some cases 
presented with a more severe disease course compared to patients <60 
years, a more benign course, especially concerning skin involvement, has 
been reported by others (120-122). Despite a more severe lung involvement 
and a delayed diagnosis in the late onset group, the disease remained stable 
in patients >75 years (122).  
In this study, we describe disease characteristics, progression and mortality of 
late onset SSc in a larger patient cohort by analyzing the large collection of 
the EUSTAR database.  
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6.2 PATIENTS AND METHODS 
 
Data sample 
We reviewed the minimal essential dataset of the EUSTAR database. The 
recruitment, structure and content of the database have been described 
previously (117). For SSc classification, ACR criteria and clinical subsets were 
defined according to LeRoy et al. (97). All participating centres have obtained 
ethics committee approval and enter data for all consecutively consenting 
patients. 
 
Definitions 
Late onset SSc was defined as age ≥75 years at onset of first non-Raynaud’s 
phenomenon. This age cut off has been chosen as representative for geriatric 
patients and in accordance with previous studies (122). First onset of non-
Raynaud’s phenomena was chosen to assess specifically the first occurrence 
of manifest organ involvement.  
 
Data analysis 
Patients were dichotomised according to age (< or ≥75 years) and data 
analysed cross-sectionally at study entry. We analysed follow up and survival 
data in all patients with ≥1 follow up visits. Both ACR criteria positive and 
negative patients were included in the main dataset in order to keep atypical 
or early SSc cases in the analysis. As a sensitivity analysis, we repeated our 
analysis limited to the subset patients with positive ACR criteria only.  
Dyspnoea was defined as NYHA grade 3 or 4, arterial hypertension as blood 
pressure measured >140 mmHg systolic or >90 mmHg diastolic. Pulmonary 
fibrosis was diagnosed by computer tomography. Lung restriction was defined 
as vital capacity <80%. PH (defined as systolic pulmonary artery pressure >40 
mmHg), diastolic dysfunction and reduced left ventricular ejection fraction 
(LVEF) were diagnosed according to echocardiographic results reported by 
the cardiologist. Patients without tricuspid regurgitation were considered as 
not having PH. For disease course analysis endpoints were defined as 
relative DLCO decline of ≥25% from baseline or mRSS decline of ≥3 points, 
which corresponded to 25% of the median baseline mRSS in the cohort.  
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Statistical analysis 
Discrete variables are expressed as counts and continuous variables as 
medians and interquartile ranges (IQR). Two-group comparison was 
performed with Wilcoxon-Mann-Whitney tests and a Kruskal-Wallis one-way 
analysis of variance was used for multiple-group comparisons. Associations of 
late onset SSc and other factors with PH were calculated in logistic regression 
models. We used unadjusted models and multivariate models adjusted for 
confounders and report odds ratios (OR). Effect modification of late onset SSc 
for the association of diastolic dysfunction and PH was tested by including an 
interaction term into the multivariate regression model. Because the frequency 
of missing data was low (<2-5% per variable and <10% for the multivariate 
model), we only present a complete case analysis and did not perform 
imputation of missings. All testing was two-tailed and p values less than 0.05 
were considered significant. All calculations were performed using STATA 
11.0 (Stata Corp, College Station, Texas).  
 
 
6.3 RESULTS 
 
Basic description 
 
At the time of data censoring (1st of June 2009), 8,554 patients were included 
in the EUSTAR database. 123 patients with a late onset of non-Raynaud’s 
phenomenon at an age of ≥75 were identified. Of these, 74.3% fulfilled the 
ACR criteria for SSc whereas ACR criteria were fulfilled in 84.4% of the 
patients <75 years (p=0.002) (table 1). The median disease duration both of 
Raynaud’s (4.4 (IQR 2-14) vs. 10.1 (IQR 4-20) months; p=<0.01) and non-
Raynaud’s phenomena (6.8 (IQR 2.8-14.3) vs. 2.1 (IQR 0.8-3.0) months; 
p=<0.01) at diagnosis was lower in the late onset group. The median disease 
duration of non-Raynaud’s phenomena symptoms at study inclusion was also 
lower in the late onset group (30 (IQR 15-48) vs. 75 (IQR 36-144) months; 
p=0.01).  
Significantly more patients in the ≥75 years group had limited SSc (74.1% vs. 
58.2%: p=0.001) whereas 17.8% vs. 32.5% suffered from diffuse disease 
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(p=0.001). The late onset group had a higher proportion of positive anti-
centromere-autoantibodies (54.2% vs. 33.4%; p<0.001). Anti-Scl70 auto-
antibodies were more prevalent in the younger group 32.3% vs. 23.0% 
(p=0.034). ANA positivity was similar in both groups (94.2 vs. 92.1%; p=0.4). 
Significant differences for the same covariates were also found in the subsets 
of ACR criteria positive patients.  
 
 
 Age <75 Age ≥75 p value 
Total number of patients 8431 123  
Demographic characteristics 
   
Average age at inclusion, median (IQR) 55 (45.6-64.8) 79.6 (78.2-81.7) <0.0001** 
Female Sex (%) 86.4 89.3 0.36 
Clinical characteristics 
   
Clinical subtype    
 - limited (%) 58.2 74.1 0.001** 
 - diffuse (%) 32.5 17.8 0.001** 
 - other (%) 9.1 8 0.67 
Disease History 
   
Age at onset of Raynaud’s phenomenon 
(years) 41 (28-52) 75 (64-78) <0.01 
Age at onset of non-Raynaud’s 
phenomenon (years) 45 (33-56) 78 (76-80) <0.01* 
Disease duration of non-Raynaud’s 
phenomenon at diagnosis (months) 6.8 (2.8-14.3) 2.1 (0.8-3.0) <0.01 
Duration of Raynaud’s phenomenon at 
diagnosis (months) 10.1 (4.4-20.4) 4.4 (2.2-14.5) <0.01 
ARC criteria fulfilled 84.4 74.3 0.002* 
Autoantibody status 
   
-       Anti-centromere (%) 34.4 54.2 <0.001** 
-       Anti-Scl-70 (%) 32.3 23 0.034* 
-       ANA  (%) 92.1 94.2 0.4 
 
Table 1. Demographic features at inclusion according to SSc onset by age at first non-
Raynauds disease feature. 
 
 
 
 
 
 
 
 131 
Clinical features 
 
The median mRSS was similar in both age strata (7 vs. 7; p=0.57) (table 2). 
The late onset group had significantly less digital ulcers (22.1% vs. 30.1%; 
p=0.03). Patients with late onset SSc had higher rates of arterial hypertension 
(40.6% vs. 20.2%; p<0.001), abnormal diastolic function (29% vs. 16.1%; 
p<0.001) and conduction blocks (9.7% vs. 21.8%; p<0.001). PH was more 
prevalent in the late onset group (35% vs. 20%; p<0.001) whereas there was 
no difference in median DLCO in both groups (53% vs. 45%; p=0.3); the late 
onset group did not suffer more frequently from dyspnoea (40.9% vs. 34.3%; 
p=0.13). Similar results and statistical significant differences were also found 
in the subset of ACR criteria positive patients, except for CK elevation, which 
was similar in both groups. 
To investigate whether late onset SSc was an independent risk factor for PH 
we calculated logistic regression analysis (supplementary data). Late onset 
SSc was a significant predictor for PH with an unadjusted Odds ratio of 2.1 
(95%CI 1.5-3.1). In addition, we found reduced LVEF (OR 4.78 (95%CI 3.90-
5.86), abnormal diastolic function (OR 3.4 (95%CI 3.0-3.8), lung fibrosis (OR 
2.7 (95%CI 2.5-3.1), conduction block (OR 2.64 (95%CI 2.2-3.0) and arterial 
hypertension (OR 1.82 (95%CI 1.55-2.14) to be significant univariate 
predictors for PH. All those factors remained independent predictors for PH in 
multivariate logistic regression analysis. We found no evidence for effect 
modification of late onset SSc (p of interaction term = 0.2), indicating that 
diastolic dysfunction is a risk factor for PH in all age groups. 
 
   
Parameter Age <75 Age ≥75 P value 
MRSS 7 (3-14) 7 (3-12) 0.57 
Synovitis (%) 15.8 15.5 0.94 
Joint contracture (%) 30.1 26.4 0.38 
Digital ulcer (%) 31.3 22.1 0.03* 
Tendon friction rubs (%) 10.5 10 0.84 
Muscle weakness (%) 25.7 21.4 0.28 
Muscle atrophy (%) 12.8 10.6 0.46 
Proteinuria (%) 5.8 6.7 0.68 
Raynaud’s phenomenon (%) 95.2 92.6 0.19 
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Table 2. Prevalence of clinical features in patients aged ≥75 vs. <75 years. Data are 
presented as median (interquartile range). 
 
 
 
Disease course  
 
All patients with ≥1 follow ups were analyzed with respect to the course of 
DLCO and mRSS. Severe and moderate impairment of DLCO (defined as a 
DLCO < 50% and <65%) was found in 20% and 22% of late onset patients, 
compared to 20% and 27% of control patients. During follow up, 17% of late 
onset and 11% of control patients had a decline of at least 25% from baseline 
DLCO (p=0.38). Late onset patients had lower median mRSS at study 
inclusion (4 (IQR 3-7) vs 7 (IQR 4-13), p=0.002), which was also confirmed in 
multivariate analysis adjusted for disease duration (p=0.02). The decline of 3 
or more points of mRSS was also similar in both groups (28% in late onset 
patients vs. 34% of control patients (p= 0.4).  
 
 
Overall and disease-specific Mortality 
 
The overall mortality in the 4,081 patients with available follow up information 
was 6.9% (22% in the late onset group and 6.7% in the early onset group, 
Conduction block (%) 9.7 21.8 <0.001** 
Diastolic function abnormal (%) 16.1 29.6 <0.001** 
Diastolic failure (%) 5.8 6.7 0.68 
Pulmonary hypertension 
(echocardiographic) (%) 20 35 <0.001** 
Lung restrictive defect (%) 30.7 29.8 0.83 
Lung fibrosis (%) 36.4 30.1 0.16 
Esophageal symptoms (%) 67.0 59.8 0.09 
Intestinal symptoms (%) 23.2 26.2 0.77 
Renal crisis (%) 2.2 0.82 0.29 
Dyspnoea (%) 34.3 40.9 0.127 
Palpitation (%) 23.8 21.3 0.50 
CK elevation (%) 8.2 3.3 0.05* 
Arterial hypertension (%) 20.2 40.6 <0.001** 
Elevated acute phase reaction (%) 29.9 44.5 0.001** 
DLCO (% of normal) 53(-76) 45 (-73) 0.30 
Reduced left ventricular function (%) 5.2 6.3 0.6 
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p<0.001). Overall, 178 deaths (63%) were attributed to SSc. The SSc-specific 
mortality rate was 12.2% in late onset patients with a median survival time of 
49 months (IQR 22-92) and significantly lower in early onset patients (4.3%, 
p=0.01), but with a shorter median survival of 41 months (IQR 22-73). 
 
 
 
 
6.4 DISCUSSION 
 
This study aimed to characterize clinical features, disease progression and 
mortality in late onset SSc. Unlike reported in previous studies, SSc in the late 
onset group was diagnosed earlier then in the control group which might be 
due to a higher frequency of medical consultation or less extensive and 
invasive diagnostic investigation in this subgroup (122). Patients with a late 
onset suffered more frequently from limited SSc and had significantly higher 
rates of anti-centromere autoantibodies. Despite the higher prevalence of 
limited disease, they had less digital ulcers. This suggests a milder disease 
course in late onset SSc patients but might be biased by a shift of patients 
with mild disease into the late onset group and the shorter disease duration at 
study inclusion, respectively. Conversely, PH was more prevalent in late onset 
SSc. However, diastolic dysfunction, arterial hypertension and conduction 
blocks which were also more prevalent in the late onset group, can lead to left 
ventricular hypertrophy and thus result non-specifically in PH (123). 
Unfortunately, right heart catheterization was performed in none of the late 
onset patients. The dataset in the present form did not allow us to determine 
whether the higher frequency of diastolic dysfunction and conduction blocks in 
the late onset group was caused by left ventricle hypertrophy or cardiac 
fibrosis due to SSc. Also, false negative results from echocardiography due to 
the absence of detectable tricuspid regurgitation jet cannot be excluded, 
although there are no data to suggest that this would affect elderly SSc 
patients more than younger patients. The course of both interstitial lung 
disease and the skin involvement remained stable in the majority of both 
groups. This is in line with previous reports of a stable course of signs in 
elderly SSc, but low mRSS values especially found in limited SSc are 
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relatively unsensitive and therefore only of limited value as a marker for 
disease progression (122).  
ACR criteria were fulfilled in fewer patients in the late onset group. This might 
indicate that, apart from an earlier study inclusion, older SSc patients suffer 
from a more atypical disease course, possibly influenced by co-medication or 
co-morbidities such as atherosclerosis. Studies in patients with late onset 
systemic lupus erythematosus (SLE) have shown similar results where they 
had more frequently Raynaud’s phenomona, arterial hypertension, organ 
damage and a higher mortality (124). Conversely, and in accordance with the 
present findings, the clinical course of late onset SLE was described as less 
aggressive (124). It is also noteworthy that Raynaud’s phenomenon in the 
elderly has different characteristics and pathogenic mechanisms compared to 
younger individuals (125, 126). 
As expected, more patients died in the older group. Taken into account the 
international nature of the EUSTAR database, mortality could not be 
compared with an available age-matched control group. Unexpectedly, in 
patients whose death was attributed to SSc, the median survival time was 
longer in the older patients, furthermore suggesting a more protracted course 
of SSc in the elderly.  
Limitations of this study include missing information concerning treatment 
modalities and co-medication, and a possible bias related to differences in 
diagnostic work-up and treatment of younger compared to older patients. 
Inter-individual and centre bias might also influence the results.  
Taken together, limited disease and PH measured by echocardiography are 
more prevalent in the elderly, but these patients suffer less from digital ulcers. 
SSc unrelated left heart hypertrophy has to be considered especially in late 
onset SSc before the diagnosis of PH can effectively be made and treatment 
started, respectively.   
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6.5 KEY MESSAGES 
 
In late onset SSc, the limited subtype and anti-centromere autoantibodies are 
more prevalent but patients suffer less from digital ulcers. 
PH is partly influenced by underlying cardiovascular co-morbidity such as 
arterial hypertension or diastolic dysfunction. 
Although the mortality is higher in late onset SSc, the time from diagnosis to 
death is longer compared to the control group.  
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CHAPTER 7 
 
 
CONCLUSION 
 
SSc is a complex multisystem disease. It is characterized by the interplay 
between inflammatory and autoimmune processes and influenced by intrinsic 
factors such as genetic predisposition, gender, age as well as extrinsic factors 
like environmental triggers, drugs or infection. 
This piece of work contributes to the understanding of the orchestration of 
inflammation in SSc and the transition from inflammation to fibrosis in several 
aspects. 
Chapter 1 describes multicolour flow cytometry of fresh skin biopsies of SSc 
patients. This technique has been applied in SSc for the first time. Flow 
cytometry of the skin permitted the analysis of significantly higher number of 
dermal cells and a thorough description of their phenotype, compared to 
immunohistochemistry.  
Lymphocyte infiltration correlated with skin thickening in a small cohort of 13 
SSc patients, the highest lymphocyte numbers occurring in patients with 
severe diffuse SSc. In contrast, higher numbers of macrophages were found 
in patients with limited disease. This is in line with previous findings of 
immunohistochemistry studies and confirms the hypothesis that diffuse and 
limited SSc have a distinct pathogenesis. Patients with limited SSc typically 
have clinical signs of vasculopathy such as digital ulcers, Raynaud’s 
phenomenon and pulmonary hypertension and show signs of enhanced 
atherosclerosis. The observation of macrophage infiltration here is similar to 
macrophage invasion in atherosclerosis, notably in atherosclerotic plaques.  
How do lymphocytes then trigger fibrosis? The hypothesis of this study was 
that lymphocytes in SSc dermis 1. secrete profibrotic cytokines and 2. trigger 
differentiation from fibroblasts to myofibroblasts. We expected a Th2 weighted 
immune response, possibly also increased amounts of T-regulatory cells, as 
the latter are, despite impaired function, increased in peripheral blood. 
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We found that TNF-R are overexpressed in the dermis and blood of SSc 
patients. Whereas TNF-R1 was upregulated on the cell surface, the induction 
of TNF-R2 expression was observed in most diffuse SSc patients. Other 
studies showed TNF-R2 expression on T-regulatory cells. We therefore 
postulate that dermal lymphocytes at least try to exhibit a regulatory function, 
probably as an attempt to resolute ongoing inflammation. 
Functional analysis using TNF-R1 and –R2 selective TNF mutants showed a 
distinct cytokine expression pattern in lymphocytes compared to healthy 
controls: upon TNF-R stimulation. Both important profibrotic cytokines and 
growth factor IL-6 and TNF-beta were higher expressed on SSc lymphcytes. 
TNF-R1 seems to trigger IL-6 expression and TNF-R2 primarily stimulates 
TGF-beta expression. The exact subcellular signaling events are elusive but it 
is likely that NFkB is involved as transcription factor. Interestingly, naturally 
occurring IL-10 production after antigen-specific stimulation (here by CD3/28 
beads) after TNF-R2 stimulaton was impaired in SSc lymphocytes. This 
implicates that on the one side we observe a profibrotic state of SSc 
lymphocytes (by increased expression of IL-6 and TGF-beta) and on the other 
side a reduced anti-inflammatory capacity of SSc lymphocytes. 
As a proof of concept, we show in a SSc patient that after autologous HSCT, 
CD3 cell infiltration decreased clearly and so did their TNF-R expression and 
as well IL-6 expression. Myofibroblast infiltration was also decreased after the 
intervention, supporting our hypothesis.  
This is  in line with 1. animal models of SSc where TNF-blockade inhibits the 
development of SSc, and 2. clinical findings in humans where a trend towards 
a decreasing skin thickening and reduced dermal collagen production was 
observed after treatment with infliximab. In the latter trial, however, no 
significance of anti-TNF treatment could be observed. Why did this happen? 
We postulate that anti-TNFalpha treatment was performed too late as the 
patients suffered from SSc for several years in average. Possibly, an earlier 
treatment would have been more efficient. Secondly, TNF-R2 is mainly 
stimulated via membrane bound TNFalpha e.g. on infiltrating macrophages or 
resident mast cells. Anti-TNFalpha compounds might not have been able to 
diffuse into the fibrotic skin and might not have sufficiently inhibited membrane 
bound TNFalpha. Third, we think that due to different pathogenic aspects, not 
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all SSc patients necessarily benefit from TNFalpha blockers. Our work here 
displays the fact that not all 13 patients had an upregulation of TNF-R and the 
grade of inflammation is variable in each individual. Maybe only patients with 
a high TNF-R status benefit from this treatment. As currently discussed in 
other diseases, a more personalized therapeutic approach will be required 
also for SSc patients. 
Taken together, both animal models and clinical oberservations in humans 
support the profibrotic role of TNFalpha-costimulated lymphocytes.  
The conclusion of these data is the following: drug delivering of TNFalpha-
inhibitors into fibrotic tissue should be improved, e.g. by a small molecule 
specifically inhibiting TNF-R2. Also, compounds in direction of supporting the 
resolution of inflammation (such as IL-10) should be developed and the exact 
impairment in the TNF-R2 downstream signaling should be further studied.   
 
In chapter two, it is demonstrated that monocytes as members of the innate 
immune system also contribute to fibrosis by their increased expression of 
functionally active TIMP-1 and thus have an active role in the ECM turn over. 
We found out that factors in the serum trigger TIMP-1 expression, yet it is 
unclear which factors exactly are responsible for this observation.  
These findings are in line with the previously described activation of 
monocytes in blood and tissue where monocytes were shown to bear a type-1 
interferon fingerprint (e.g. shown by a Siclec-1 expression). So we postulate 
that a type-1 interferon stimulus (e.g. in form of a viral infection) could trigger 
TIMP-1 expression. 
Further experiments would include the stimulation and subsequent inhibition 
of monocytes with interferon alpha or beta, toll like receptors and cytokines 
such as TNF-alpha, IL-6, IL-10 or IL-13. It would also be important to 
demonstrate TIMP-1 expression by monocytes or macrophages in the tissue 
e.g. by immunohistochemistry. 
 
Chapter three shows that mast cell degranulation is more prevalent in dermis 
of SSc patients and mast cells in fact are the most important source of active 
TGF-beta in the dermis in SSc. One crucial question remains what factor 
causes mast cell degranulation in SSc? Again, a possible answer could be the 
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clinical observation of patients who underwent type-1 interferon treatment and 
subsequently developed SSc. Type-1 interferons can indeed provoke mast 
cell degranulation. As a next experiment, healthy mast cells of a cell line could 
be incubated with sera from SSc patients and degranulation could be 
measured e.g. by measurement of tryptase. Then, factors in the sera can 
further be identified. The dynamic of mast cell degranulation is also of interest. 
Apparently the degranulation has a continuous low-mid level dynamic, also 
called (piece meal degranulation) rather than a full blown degranulation as 
seen in anaphylaxy. The reason for this is not clear, apart from an ongoing 
stimulus, there could be an impairment of the resolution of degranulation or a 
structural defect of mast cell vesicles, respectively. Mast cells can also 
degranulate via antigen stimulation, toll like receptors or Fc receptors. 
Therefore, their expression on the cell surface as well as downstream 
signaling of these receptors should be studied in detail in order to 
demonstrate a ‘mast cell autoimmunity’ in SSc patients. 
 
Chapter four is a clinical study following the observation of SSc cases after 
type-1 IFN treatment for multiple sclerosis or other diseases. Despite the low 
patient number this analysis is supported by several investigations where a 
type-1 fingerprint of monocytes has been found. It is demonstrated in several 
cases that SSc occurred with a delay typically of 6-12 months after IFN 
treatment. This implicates that SSc 1. could be a consequence of a viral 
infection (which is associated with high levels of type-1 IFN) and 2. this IFN 
trigger might not occur close to the SSc onset. This hypothesis is in line with 
autoantibodies which are sometimes found years before the onset of SSc.   
  
Chapter five: Age is an important factor for SSc and autoimmune diseases in 
general. The reason is ‘immunosenesence’, the fact that our immune system 
alters during our life span. Despite controversial data, the dogma has been 
that in older patients SSc has a worse course. In this project I used data from 
the world largest SSc database EUSTAR to analyze clinical features and 
outcome of SSc patients ≥75 years. In contrast to the above mentioned 
dogma, patients with a late onset of SSc in fact had relatively stable course of 
SSc. Older individuals at diagnosis of SSc live longer compared to younger 
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individuals. As a conclusion, older individuals that are often more fragile with 
more comorbidity and polymedication might need a less intense or distinct 
treatment strategy. 
This was a purely clinical study project, but opens the door for further 
laboratory based research questions: e.g. in which functional status is the 
innate or adaptive immune system in older SSc patients versus younger or 
age matched healthy individuals?  
Taken together, I conclude that new treatment strategies should build on 
knowledge of in the orchestration of inflammation in SSc as well as SSc 
subtypes, time course and age of the patients. 
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Schematic illustration of the context between the data gained in this thesis. 
Mast cells as ‘connective tissue sensors’ are activated in SSc and degranulate e.g. 
as response to an exogenous or endogenous type-1 interferon stimulation. Mast cell 
granula contain TGF-beta and various other cytokines, growth factors and tryptase. 
This leads to the attraction of inflammatory cells, vasodilatation and probably also 
fibrosis via the ongoing secretion of TGF-beta. Monocytes are early infiltrating cells 
typically secreting proinflammatory cytokines. We show however that monocytes also 
secrete functionally active TIMP-1, therefore inhibiting MMP-mediated matrix 
degradation. Monocytes might also differentiate into mesenchymal cells such as 
myofibroblasts. Lymphocytes are activated in SSc skin, which demonstrated by their 
expression of TNF-R2. In first line, activated T-lymphocytes raise an adaptive 
immune response by stimulating B-cells to produce antibodies. Activated 
lymphocytes also secrete IL-10 to resolve the inflammation, an effect which is 
triggered via TNF-R2 stimulation. The failure of resolving inflammation in SSc leads 
to persisting expression of TGF-beta by mast cells, TIMP-1 by monocytes and IL-10 
by lymphocytes. The ‘net effect’ of this cytokine imbalance results in fibrosis.  
SMA: smooth muscle actin, TGF-beta: transforming growth factor, ET-1: endothelin-
1, TIMP-1: tissue inhibitor of metalloproteinases, TNF: tumor necrosis factor. TNF-R: 
tumor necrosis factor receptor, MMP: metalloproteinase.   
  
 
